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Abstract 
 
The completion of the human genome project has marked a new beginning in biomedical 
sciences. As human cancer is a genetic disease, the field of oncology has been one of the first to be 
impacted by this historic revolution. High-throughput mutational profiling of tumors has provided 
an unprecedented amount of information on genetic changes leading to cancer and has already 
revolutionized the way lung cancers are classified and treated. Fundamental for successfully 
translating the information uncovered by these genetic studies into the clinic is the molecular and 
functional characterization of the identified genetic lesions. As part of these efforts, the goal of my 
thesis studies was to gain an understanding of how genetic lesions affecting receptor tyrosine 
kinases (RTKs) contribute to treatment response and survival differences observed in lung tumors. 
Phosphorylation of tyrosine residues in proteins was first described in 1979 as an activity of 
a viral transforming gene product. Soon afterwards RTKs were recognized to play a role in 
transducing growth factor signals across the plasma membrane. Over the past 50 years, the 
importance of RTKs has been demonstrated in multiple studies, and increasing amounts of data 
have implicated the deregulation and malfunction of these signaling proteins in a variety of 
diseases including lung cancer. Although highly similar in structure and regulation, different RTKs 
exert distinct biological functions. The ability of RTKs to function within common pathways, yet 
induce diverse phenotypic responses, has largely been attributed to: 1) differences in cellular 
context, as signaling proteins are differentially expressed in distinct cell types; 2) the strength and 
temporal properties of signaling; and 3) differences in binding sites for effector molecules.  
In addition to these mechanisms, we discovered that intrinsic differences in RTK substrate 
specificity could also play a role in modulating functional differences among RTKs. In particular, 
we found the SOCS3 residue Y165 to be differentially phosphorylated by certain RTKs such as the 
platelet derived growth factor receptor (PDGFR) and the epidermal growth factor receptor (EGFR). 
The increased phosphorylation leads to ubiquitination and proteasome-dependent degradation of 
SOCS3. As SOCS3 is one of the major negative regulators of IL-6 mediated signaling, degradation of 
SOCS3 by PDGFR-mediated phosphorylation results in potentiation of IL-6 signaling, and 
phenotypically in the acquisition of mesenchymal-like features and increased metastatic potential 
as well as erlotinib resistance. 
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CHAPTER I 
INTRODUCTION  
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Chapter 1: Introduction 
1.1. Overview 
There is a broad consensus that cancer is, in essence, a genetic disease, and that 
accumulation of molecular alterations in the genome of somatic cells is the basis of tumor 
onset and progression. Hence, the availability of the human genome sequence and progress 
in DNA sequencing technologies has dramatically improved knowledge of this disease and 
in particular of lung cancer. These new insights are transforming the field of lung oncology 
at multiple levels. First, characterization of the lung genomic landscape is redesigning lung 
tumor taxonomy by moving it from a histologic- to a genetic-based level. Second, the 
success of cancer drugs designed to target the molecular alterations underlying lung 
tumorigenesis (e.g., erlotinib in the case of EGFR oncogenic mutations, and crizotinib in the 
case of ALK4 translocations) has proven that somatic genetic alterations can be exploited as 
targets for therapy. In addition, tumor genotyping is helping clinicians to tailor cancer 
treatments by matching patients with the best available treatment for their tumors.  
In this chapter, I will review the progress that has been made in characterizing the 
lung genomic landscape with particular emphasis on genetic abnormalities that lead to 
deregulation of RTKs activities. Before going into detail on how novel integrated 
approaches have allow a compressive and systematic evaluation of genetic alterations that 
occur in lung cancer, I will briefly summarize current concepts on the molecular pathology 
of lung cancer.  
 
1.2 Molecular pathology of lung carcinoma: current concepts 
Lung cancer is the leading cause of cancer death in the United States and in the 
world, with more than 1.32 million fatalities annually (Parkin et al. 2005). In 2008, more 
patients in the U.S. died of lung cancer than colorectal, breast, and prostate cancer combined 
(Jemal et al. 2008). It is estimated that lung cancer accounts for 31% of all cancer deaths in 
men and 26% in woman (Herbst and Bunn 2003; Fuster and Sandler 2004; Jemal et al. 2008; 
American Cancer Society 2012). For patients with local disease, the median 5-year survival is 
49%; with regional disease it decreases to 16%; and in patients in whom the tumor has 
already spread to the lymph nodes (distant disease) it plummets to 2% (Ries et al. 2005). The 
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more favorable prognoses observed in the minority of patients with localized disease can be 
attributed to the possibility of surgically removing the tumor. 
The mayor risk factor for developing lung cancer is smoking. It is estimated that 70% 
of all lung cancer patients are smokers (Fauci et al. 2009). Other risk factors include exposure 
to radon (a radioactive gas that results from the breakdown of uranium in soil and rocks), 
asbestos, chemicals or minerals such as arsenic (Samet 2009; Weiderpass 2010), and poor air 
quality especially in large cities and heavily trafficked roads (Weiderpass 2010). Chronic 
inflammatory conditions such as chronic obstructive pulmonary disease (COPD) have also 
been linked to an increased probability of developing lung cancer (NCI 2012). In addition to 
these extrinsic cues, epidemiological studies have also indicated that genetic and epigenetic 
factors could contribute to lung tumorigenesis as well. As an example, in non-smokers the 
frequency of non-small cell lung cancer (NSCLC) is higher in women compared to men of 
the same age and ethnicity (Wei et al. 2000). 
One of the major hurdles in the treatment of lung cancer and one of the reasons why 
this is such a deadly disease is its highly heterogeneous nature. In fact, the ways in which 
lung tumors appear, behave and respond to treatment are highly dissimilar, making each 
tumor almost one-of-a-kind.   
Interestingly, it has been long appreciated that the appearance of lung cells (i.e., 
histology) could be correlated to particular tumor behavior and with a particular anatomic 
distribution (NCI 2012). Based on these observations, lung tumors have been classified 
based on cell size and shape. In particular, as shown in Figure 1.1, lung cancer has 
traditionally been subdivided into two major types: small cell lung carcinoma and NSCLC, 
the latter accounting for almost 80% of all cases (NCI 2012). NSCLC is further classified into 
epidermoid/squamous (29%), adenocarcinoma/bronchioalveolar (35%), and large cell (9%) 
(Travis et al. 2004). Of these, squamous cell carcinoma (SQs) is often linked to a history of 
smoking and tends to be located in the middle of the lungs, near bronchial bifurcations. 
Adenocarcinomas (ADs) on the other hand are usually located in more distal/outer regions 
of the lungs and tend to grow and spread more quickly (NCI 2012).  
Yet, it has become evident that this classification is insufficient. Patients with 
histologically similar tumors have different clinical outcomes. Furthermore, tumors that 
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cannot be distinguished based on histological analysis can respond very differently to 
identical therapies.  
With the development of technologies that allow for high-throughput analysis of 
genomic data and the sequencing of the human genome, it has becoming increasingly 
understood that the frequency and distribution of mutations affecting cancer genes can be 
used to redefine the histology-based taxonomy of a given tumor type(Meyerson et al. 2010). 
Spurred by the pioneering work by the laboratories of William Sellers, Matthew Meyerson 
and Daniel Haber, classification of lung cancer is now moving from a histologic- to a 
genetic-based. These efforts were largely inspired by the clinical success of small-molecule 
inhibitors of tyrosine kinases in the treatment of human tumors (Shawver et al. 2002). 
Studies correlating the presence of EGFR oncogenic mutations in lung cancer patients that 
respond to treatment with EGFR inhibitors have suggested the importance of patient 
stratification in cancer treatment and provided an additional rationale for many cancer 
genomics projects: i.e., identify a genetic lesion and find an agent that is active against the 
lesion (Shawver et al. 2002).  
Although very promising, tailored treatment in lung cancer is highly limited by the 
paucity of therapeutic options currently available. In addition to surgical removal, common 
lung cancer treatments include palliative care, chemotherapy, and radiation therapy. The 
most frequently used chemotherapy regimens in advanced NSCLC (stage IV) are based on 
cisplatin or carboplatin treatments, in combination with gemcitabine, paclitaxel, docetaxel, 
etoposide, or vinorelbine and doxorubicin (Hirsh 2010). In addition to these chemotherapy 
drugs, the only other FDA approved drugs are the EGFR tyrosine kinase inhibitor (TKI) 
erlotinib, and the anaplastic lymphoma kinase inhibitor crizotinib (Hirsh 2010). Hence, the 
identification of novel genetic vulnerabilities of lung tumors is an important undertaking for 
the medical and scientific community.   
In conclusion, while tumors have historically been classified based on two criteria - 
localization (site of occurrence) and appearance (histology) - these criteria are currently 
being re-evaluated. In particular the presence of genetic lesions has now been proposed as 
major criteria for lung taxonomy. This transformation of lung molecular pathology will 
likely improve the precision at which lung tumors can be classified and it will help in 
tailoring therapeutic regimens based on the genetic landscape of individual tumors. 
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1.3 Toward a molecular taxonomy of lung cancer 
Key to redefining the histology-based taxonomy of lung cancer has been the 
development of technologies that allow for high-throughput analysis of genomic data. In 
this regard, the complete sequencing of the human genome has marked a new era in lung 
oncology and in biomedical science in general.  
Before elucidation of the human genome, several cancer genes, such as KRAS, TP53, 
and APC, were successfully discovered using approaches based on oncovirus analysis, 
linkage studies, loss of heterozygosity, and cytogenetics. The completion of the Human 
Genome Project in 2004 (International Human Genome Consortium 2004), which provided a 
sequence-based map of the normal human genome, together with the construction of the 
HapMap, containing single nucleotide polymorphisms (SNPs), and the underlying genomic 
structure of natural human genomic variation, dramatically accelerated the pace and depth 
at which new genetic aberrations can be identify (reviewed in Meyerson et al. 2010). Figure 
1.2 clearly illustrates the developments in the search of cancer genes, its increased pace, as 
well as the most relevant findings in this field. 
The human genome project and the subsequent large-scale cancer genomic projects 
have resulted in the development of new faster and more affordable high-throughput 
technologies as well as bioinformatics tools that allow for the analysis of sequencing data 
(Fuller et al. 2009).  
Following its development in 1977, the Sanger method for DNA sequencing (first 
generation sequencing) was the method of choice for elucidating the nucleotide sequence of 
DNA molecules for thirty years (Sanger et al. 1977). The development of next-generation 
sequencing (NGS) technologies over the past 15 years has significantly lowered the cost and 
the time required for DNA sequencing (Metzker 2010). Moreover, NGS approaches are more 
sensitive and quantitative than Sanger methods. Hence, they are capable of detecting 
somatic mutations even when present only in a subset of tumor cells as well as copy number 
variations. Nonetheless, next-generation sequencing still presents some limitations mainly 
due to the relatively high error rate in the short reads generated during the sequencing 
process and by the difficulty of assembling the generated sequence reads (Metzker 2010). 
Another application of second-generation sequencing involves utilizing nucleic acid “baits” 
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to capture regions of interest in the total pool of nucleic acids. Because most areas of the 
genome can be targeted, including exons, this allows rapid and low cost surveying of cancer 
mutations.   
The use of these technologies has revolutionized the pace and depth at which lung 
tumors are been analyzed and allowed for the generation of high-resolution genomic maps 
(Rizzo and Buck 2012). As a result we now realize that by the time a cancer is diagnosed, it 
is composed of billions of cells carrying numerous genetic mutations, including single 
nucleotide changes, small insertions and deletions, large chromosomal reorganizations, 
copy number variations and gene overexpression resulting from other mechanisms such as 
those mediated by miRNAs (Pinkel et al. 1999; Bignell et al. 2004; Garraway et al. 2005; Zhao 
et al. 2005, Maher et al. 2009).  
Overall the number of mutations uncovered by these studies is much larger than 
what initially was anticipated. It is now appreciated that only a small fraction of these 
genetic alterations are “drivers” that is, genes that drive cancer by giving cells a selective 
advantage and that in contrast the majority of genetic lesions are mutations with no 
functional role in tumorigenesis that are referred to as “passengers.” Thus, distinguishing 
drivers from passenger mutations is currently one of the main challenges in cancer genetics. 
Current efforts to address this hurdle include a combination of genetic, bio-informatic and 
functional approaches, some of which are currently being developed at CSHL. 
One of the complications in the functional characterization of cancer mutations is the 
realization that in addition to cell proliferation also self-sufficiency of growth, evasion of cell 
death (apoptosis and surveillance by the immune system), limitless replicative potential, 
sustained angiogenesis, tissue invasion and metastasis and metabolic growth are acquired 
capabilities that are similarly indispensable for tumor development and progression 
(Hanahan and Weinberg 2011). Thus, based on these new criteria the spectrum of driving 
mutations has largely been expanded.  
Interestingly, it has also been observed that in addition to promoting the malignant 
transformation of a cell, persistent up-regulation of a particular growth signal or pathway 
can also result in “oncogenic addiction” whereby the cell becomes dependent on certain 
aberrant oncogenic signaling for survival (Weinstein 2002). This presents an obvious target 
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for therapeutics: i.e., remove or inhibit the oncogenic signal and an addicted tumor cell will 
die, whereas normal “non-addicted” cells will be unaffected.  
Although incomplete, the functional characterization of some of the genetic lesions 
found in tumors has revealed that the acquisition of these cancer hallmarks is achieved by 
the deregulation of regulatory circuits that normally control cell physiology and 
homeostasis. Broadly, genes mutated in cancer that are positive regulators of these 
circuitries are referred as oncogenes, while genes that are negative regulators are referred to 
as tumor suppressor genes (TSGs).  
In addition to oncogenes and tumor suppressor genes, functional characterization of 
genes mutated in cancer has revealed the identification of a distinct class of genes involved 
in DNA repair mechanisms. Spontaneous mutations in these genes can in fact increase the 
frequency at which mutations can be accumulated. This seems particular relevant in the case 
of lung cancers as mutations in these genes in patients that are heavily smokers can results 
in the rapid occurrence of tumors. 
Although hundreds of mutations in lung cancer have been found, in the next 
sections, I will review those that occur with higher frequencies, as indicated by data 
collected in the Catalogue of Somatic Mutations in Cancer (COSMIC) (Forbes et al. 2008). In 
particular, because my studies are aimed at understanding how specific genetic alterations 
can contribute to NSCLC heterogeneity, I will limit my analysis to this specific type of lung 
cancer. 
 
1.4 The genetic landscape of lung cancer: lesions that affect DNA repair 
 Genetic lesions that affect the normal activity of genes involved in DNA repair by 
increasing the frequency of mutations in general augment the probability of developing 
cancer (Loeb 2001). This is particular relevant in the case of lung cancers caused by smoking.  
Interestingly, although cigarette smoking is the major risk factor associated with 80–
90% of all lung cancer cases, only 10–15% of heavy smokers ultimately develop lung cancer 
(Li et al. 2001; Shen et al. 2003). This suggests that besides exogenous susceptibility factors, 
endogenous factors must be involved in lung carcinogenesis. Indeed, DNA repair capacity 
appears to be significantly lower in lung cancer patients that are heavy smokers than in 
healthy controls, and is consider an independent risk factor for the development of NSCLC 
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(Wei et al 1996; Wei et al. 2000). Molecular studies have in particular identified 
polymorphisms in genes involved in detoxification processes of tobacco-derived 
carcinogens, such as the cytochrome p450 system and glutathione S transferase, showing 
that these can contribute to lung cancer susceptibility (Houlston 2000; Houlston1999). Also 
in non-smokers, deficits in repair capacity have been linked to genetic instability and 
ultimately carcinogenesis (Hecht 2002). Although conflicting data have been published, 
recent meta-analyses suggested a moderately increased risk of lung cancer for persons 
harboring CYP1A and glutathione S transferase M1 polymorphisms (Cosma et al. 1993; 
Crofts et al 1994; Houlston 2000; Houlston1999). 
 
1.5 The genetic landscape of lung cancer: lesions that affect tumor suppressor 
genes and growth inhibitory pathways 
Loss of TSG function is an important feature in lung tumorigenesis, since they are 
considered negative regulators of growth. TSGs are believed to be inactivated in a two-step 
process: LOH chromosomal deletion or translocation is usually one step, while point 
mutation or epigenetic silencing of the second allele can be the second step (Harris 1988). 
Described below are a few examples of TSGs commonly altered in NSCLC including TP53, 
CDKN2A, FHIT, RASSF1a, TSLC1, and PTEN (Figure 1.3). 
 
 TP53 
The p53 TSG is located on the short arm of chromosome 17 (17p13) and encodes a 53-
kDa protein. In normal physiology, this protein prevents accumulation of genetic damage in 
cells in response to cellular stress. p53 acts as a transcription factor inducing expression of 
downstream genes, such as the cyclin-dependent kinase (CDK) inhibitor p21KIP, GADD45 
or BAX (Laptenko and Prives 2006; Beckerman and Prives 2010; Brady et al. 2011). In a very 
simplistic view, downstream target genes of p53 regulate a cell cycle checkpoint signal that 
causes the cell to undergo G1 arrest, allowing DNA repair, or apoptosis. The oncogene 
MDM2, which is also a target gene of p53, functions as a negative feedback system, 
inactivating the p53 protein (Pomerantz et al. 1998; Zhang et al. 1998). Inactivating 
mutations in the p53 TSG are among the most common alterations in cancer (Holstein et al. 
1991). p53 mutations are often single base substitutions, occurring in the majority of the 
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cases in exons 5–8 (Holstein et al. 1991). Similar to K-RAS mutations, most p53 mutations 
are G-T transversions and there is a positive correlation between mutations and the use of 
tobacco (Gao et al. 1997). Interestingly, the incidence of p53 mutations is higher in females 
with NSCLC than in males (Toyooka et al. 2003). The precise mechanism behind this 
observation is still unclear.  
 
 TSLC1 
Recently, a tumor suppressor gene in lung cancer (TSLC1) located on chromosome 
11 (11q23.2) was identified as a new TSG in NSCLC (Kuramochi et al. 2001). TSLC1 is 
expressed in normal bronchial epithelium, whereas the protein is down-regulated in NSCLC 
(Ito et al. 2003). A classic two-hit inactivation mechanism (loss of one allele and promoter 
hypermethylation or inactivating mutations in the remaining allele) is observed in 40% of 
NSCLCs (Kuramochi et al. 2001) and is associated with poor prognosis (Fukami et al. 2003). 
TSLC1 encodes a membrane glycoprotein of the immunoglobulin superfamily (Ig-CAM) 
that participates in cell-cell adhesion (Masuda et al. 2002). Although its precise mechanism 
of tumor suppression remains unclear, it is assumed that tumor suppression is achieved by 
loss of contact inhibition. Interestingly, when TSLC1 was introduced in a cell line lacking 
this gene (A549 cells), tumor growth was suppressed in nude mice (Kuramochi et al. 2001).  
 
 PTEN 
The TSG phosphate and tensin homolog detected on chromosome 10 (PTEN), also 
called MMAC1 (mutated in multiple advanced cancers), maps to 10q23.3 and encodes a 
cytoplasmic protein that influences the phosphoinositide-3-kinase (PI-3K)/Akt pathway 
(Li et al. 1997). Loss of PTEN expression results in increased Akt activity and continued 
cell survival (anti-apoptosis) and cell proliferation (Di Cristofano et al. 1998; Stambolic et 
al. 1998). In contrast to other malignancies, such as prostate cancer, mutation in PTEN is a 
rare event in NSCLC, with a frequency of 0–16% depending on the study (Li et al. 1997; 
Forgacs et al. 1998; Hosoya et al. 1999; Kohno et al. 1998; Yokomiso et al. 1998). 
Interestingly, PTEN inactivation is more frequently detected at the protein level (17–24%) 
(Soria et al. 2002; Torres et al. 2001). Although further studies are needed one study 
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showed PTEN promoter hypermethylation in 35% primary NSCLC and in 69% of NSCLC 
cell lines (Soria et al. 2002).  
 
 LKB1 
The serine/threonine kinase LKB1 (also called STK11) is inactivated in 
approximately 30% of lung cancers and often correlates with KRAS activation, resulting in 
the promotion of cell growth and in mouse model in increased metastatic spread (Ji et al. 
2007). It functions as a TSG by regulating cell polarity, differentiation, and metastasis and 
can regulate cell metabolism. It has also been reported to inhibit the mTOR pathway 
(Sanchez-Cespedes 2011). 
 
1.6 The genetic landscape of lung cancer: oncogenes and growth-stimulatory 
pathways 
Genome-wide mutational analyses suggest that the mutational landscape of cancer 
is made up of a handful of genes that are mutated in a high fraction of tumors, sometimes 
referred to as “mountains,” while most mutated genes are altered at relatively low 
frequencies, sometimes referred to as “hills”. The mountains probably give a high 
selective advantage to the mutated cell, and the hills might provide a lower advantage, 
making it hard to distinguish them from passenger mutations. Bioinformatic studies 
suggest that the mountains and hills can be grouped into sets of pathways and biologic 
processes. Pathway analyses have allowed the stratification of mutated genes in NSCLC to 
core pathways (Figure 1.3). Among them, the KRAS, Wnt, ALK, NKX2.1 and RTKs 
mediated pathways are the most frequently deregulated in NSCLC.  
 
 RAS-RAF-MEK signaling pathway 
RAS-RAF-MEK is another downstream signaling pathway that is activated by 
RTKs and has been widely implicated in human cancers. In a simplified view, in response 
to growth factor signals, activated RTKs trigger GTP binding by RAS GTPases. GTP-
bound RAS subsequently leads to phosphorylation-mediated RAF activation, which in 
turn signals MEK and ERK signaling molecules that facilitate cell growth and 
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proliferation. The most commonly mutated RAS isoform in human cancer is KRAS 
(Quinlan et al. 2008). Activating mutations in KRAS cause irreversible binding of KRAS to 
GTP, resulting in constitutive activation of the signaling molecule. According to the 
COSMIC database, KRAS mutations have been identified in 22% of NSCLC 
adenocarcinomas and are less frequently associated with squamous cell carcinomas 
Forbes et al. 2008). More than 90% of KRAS mutations occur in exon 1, with a much 
smaller fraction occurring in exon 2. Because NSCLC tumors harboring KRAS mutations 
are refractory to EGFR inhibitors, detection of KRAS mutations is a negative indicator of 
response to anti-EGFR therapies (Van et al. 2007; Zhu et al. 2008; Massarelli et al. 2007; 
Eberhard et al. 2005). 
BRAF, which encodes a serine/threonine kinase, is the most commonly mutated 
gene in melanoma. In NSCLC, BRAF mutations have also been identified. 2% of squamous 
carcinomas harbor mutations mostly in exon 11, while 4% of adenocarcinomas express 
mostly V600E mutation in exon 15 (74%) (Forbes et al. 2008). The locations of these 
mutations suggest different mechanisms of BRAF activation. The V600E mutation resides in 
the BRAF activation domain, whereas the exon 11 mutation affects a residue in the AKT 
phosphorylation site and likely results in loss of inhibitory phosphorylation by AKT (Brose 
et al. 2002). 
Although rare, mutations in the MEK1 kinase, which is downstream of KRAS and 
BRAF, may also play a role in NSCLC. A single somatic activating point mutation in exon 2 
of MEK1 was identified in 2 of 207 primary lung tumors with no other mutation (Marks et 
al. 2008). Screening of lung cancer derived cell lines identified an additional point mutation 
in exon 2 of MEK1 in the NCI-H1437 cell line. 
 
 WNT signaling pathway 
Wnt proteins form a family of highly conserved secreted signaling molecules that 
regulate cell-to-cell interactions during development. As currently understood, Wnt 
proteins bind to receptors of the Frizzled and LRP families on the cell surface. Through 
several cytoplasmic components, the signal is then transduced to beta-catenin, which enters 
the nucleus and forms a complex with TCF to activate transcription of Wnt target genes. 
Mutations in exon 3 of the gene encoding β-catenin mediate accumulation and constitutive 
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activation of β-catenin (Fujimori et al. 2001). These mutations have been identified in 10% of 
NSCLC adenocarcinoma. No such mutations were found in the squamous subtypes (Miller 
et al. 1999, Forbes et al. 2008). The Wnt signaling pathway therefore represents a potential 
tumorigenesis mechanism in lung adenocarcinoma, alternative to RTK activation. 
 
 Anaplastic lymphoma kinase (ALK)  
ALK is a RTK that is commonly associated with oncogenic gene fusions in 
hematologic disorders, such as anaplastic large cell lymphoma. Translocations involving 
ALK have been identified with at least 11 partner genes in various hematologic and solid 
tumor malignancies. The most frequent of these results from adenosine to a thymine (2;5) 
chromosomal translocation that fuses ALK on chromosome 2 with the nucleophosmin 
(NPM) gene on chromosome 5 giving rise to the NPM-ALK fusion protein (Morris et al. 
1994; Morris et al. 1997). This type of translocation generally leads to elevated expression 
levels of ALK and subsequently causes increased activation of the PI3K-AKT signaling 
pathway, a signaling pathway believed to be crucial in malignant transformation driven by 
ALK (Greenland et al. 2001; Slupianek et al. 2001).  
Recently, chromosome 2p inversions resulting in ALK translocations were also 
identified in NSCLC (Soda et al. 2007). ALK translocations have been associated with ∼7% 
of adenocarcinomas and are only rarely seen in other NSCLC subtypes. Similarly to EGFR 
oncogenic-mutations, ALK translocations may also have a significant association with acinar 
histology and have also been found in BACs (Inamura et al. 2008; Inamura et al. 2009). The 
echinoderm microtubule-associated protein-like 4 gene (EML4) is the partner gene in nearly 
all ALK fusions found in NSCLC thus far, although in a few other patients KIF5B-ALK 
fusion was also identified (Sanders et al. 2010). To date, 15 variants of the EML4-ALK fusion 
transcript involving at least eight different EML4 exons have been described (Sanders et al. 
2010; Perner et al. 2008; Shaw et al. 2009; Choi et al. 2008; Koivunen et al. 2008; Wong et al. 
2009; Takahashi et al. 2010). Interestingly, fusion variants of EML4-ALK have been 
associated with a unique histo-type. For example, a recent study found variant 1 associated 
with mixed papillary with BAC component histologies and variant 2 with acinar histologies 
(Inamura et al. 2008).  
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 NKX2-1 (TITF1) 
Genome-wide screens for DNA copy number changes in primary NSCLCs found 
multiple examples of amplification at 14q13.3—and subsequent functional analysis (siRNA 
knockdowns in NSCLCs) identified NKX2-1 (also termed TITF1) as the most likely target of 
amplification in lung cancer (Kendall et al. 2007; Kwei et al. 2008; Weir et al. 2007). NKX2-1 
encodes a lineage-specific transcription factor essential for branching morphogenesis in lung 
development and the formation of type II pneumocytes, the cells lining lung alveoli. 
Amplification of tissue-specific transcription factors in cancer has been observed in AR 
in prostate cancer, MITF in melanoma, and ESR1 in breast cancer. These findings have led to 
the development of a “lineage-dependency” concept in tumors whose survival and 
progression of a tumor is dependent upon continued signaling through specific lineage 
pathways (i.e., abnormal expression of pathways involved in normal cell development) 
rather than continued signaling through the pathway of oncogenic transformation as seen 
with oncogene addiction (Tanaka et al. 2007). Counter intuitively, recent work from Tyler 
Jacks lab indicated that silencing of NKX2-1 can increase the metastatic spread of tumors 
(Winslow et al. 2011).   
 
 Receptor tyrosine kinases (RTKs) 
Receptor tyrosine kinases, including EGFR, PDGFR, MET and FGFR, are among the 
most frequently mutated genes in NSCLC (Ding et al. 2008). Altogether they account 
approximately for 60% of all oncogenic mutations so far identified and affect approximately 
40% of all NSCLCs. 
In particular, EGFR is overexpressed in 40% of NSCLC, and its expression is 
correlated with poor prognosis (Ohsaki et al. 2000; Nicholson et al. 2001; Hirsch et al. 2003; 
Arteaga 2003; Sharma 2007). In the majority of cases, overexpression of EGFR has been 
linked to amplification of chromosomal region 7p12, where the EGFR gene is located (Testa 
& Siegfried 1993). In addition to EGFR, its cognate ligands (EGF and TGF-alpha) are also 
frequently overexpressed in NSCLCs. This establishes autocrine loops leading to receptor 
hyperactivity, hence unleashing EGFR activation from its dependence on the tumor-
microenvironment (ligand availability) (Putnam et al. 1992; Rusch et al. 1993). 
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In 2004, heterozygous mutations in the EGFR gene were detected in NSCLC (Lynch 
et al. 2004; Pao et al. 2004; Sordella et al. 2004). These mutations were clustered around the 
kinase domain of the EGFR kinase and were strongly associated with clinical response to 
gefitinib and erlotinib, two small-molecule EGFR kinase inhibitors. These mutations could 
be subdivided into three groups: the substitution mutation G719S located in the glycine-rich 
nucleotide triphosphate-binding P loop, small in-frame deletion mutations in exon 19 and 
the substitution mutation L858R that is located in the activation loop (Lynch et al. 2004; Paez 
et al. 2004; Sordella et al. 2004).  
According to data collected in the COSMIC database (Forbes et al. 2008), EGFR 
mutations are found in approximately 40% of adenocarcinomas, 30% of mixed 
adenosquamous carcinomas, and ≤5% of squamous or large-cell carcinomas. Furthermore, 
studies have also demonstrated significant association with tumors with bronchio-alveolar 
carcinoma (BAC) features, acinar patterns, and papillary subtypes of adenocarcinoma 
(Chantranuwat et al. 2005; Blons et al. 2006; Ohtsuka et al. 2006; Sakuma et al. 2007). 
Interestingly, these mutations occur more frequently overall in non-smokers (∼95-75% in 
nonsmokers, 5–15% in smokers), in women and in patients of Asian ethnicity (Lynch et al. 
2004). Although the frequency of EGFR gene mutations in NSCLC is roughly 10% in 
Caucasian patient populations, the proportion in East Asian patients is around 30% (Janne 
et al. 2005). Interestingly, these features match with those of patients who respond to EGFR 
tyrosine kinase inhibitor (TKI) treatment in initial phase II trials (Fukuoka et al. 2003; Kris et 
al. 2003; Miller et al. 2004; Soulieres et al. 2004). 
Functional experiments in vitro and in mouse models showed that these mutations 
are oncogenic. Ectopic expression of EGFR mutations in an adenocarcinoma cell line 
increases the cell’s sensitivity to EGFR inhibitors (Paez et al. 2004). Sordella et al. showed 
that lung cancer–derived EGFR mutations activate the anti-apoptotic Akt and STAT3/5 
pathways, providing a link between these mutations, malignant transformation and 
“addiction” to anti-apoptotic pathways (2004). Interestingly, by specifically silencing the 
mutant EGFR allele using small interfering RNA technology, they were able to show 
induction of apoptosis in EGFR-mutant but not wild-type cells and, thus, a dependency of 
EGFR mutants on this oncogene. It is still unresolved whether the mechanism by which the 
mutations confer responsiveness to EGFR TKI is by changing the biochemical properties of 
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the kinase, by targeting an activated kinase on which the cell has become strictly dependent, 
or both.  
Unfortunately, all NSCLC patients treated with the EGFR TKIs gefitinib or erlotinib 
will eventually relapse and succumb to the disease (Kobayashi et al. 2005; Pao et al. 2005a). 
Similar to CML patients who acquire resistance to imatinib caused by the emergence of 
secondary mutations in the BCR-ABL kinase domain, NSCLC patients treated with EGFR 
TKI, also acquire resistance, attributed to the presence of a secondary mutation in the EGFR 
kinase domain (T790M). When the T790M mutation, analogous to the T315I mutation in 
CML, was introduced into CHO-K1 cells, resistance to EGFR TKI treatment is observed 
(Blencke et al. 2005). Interestingly, crystal structure of EGFR harboring the T790M mutation 
indicated that the threonine residue at position 790 bind erlotinib via a bridging water 
molecule (Stamos et al. 2002). The substitution by a methionine reduces the affinity of 
erlotinib and gefitinib to EGFR and hence dampens the cell’s sensitivity to EGFR TKI. 
Second generation inhibitors have now been developed and shown to effectively kill cells 
carrying the T790M resistance mutation in concentrations that might be achievable in 
patients (Kobayashi et al., 2005; Balak et al., 2006; Kosaka et al., 2006). Still, clinical trials 
with these inhibitors have so far failed to show efficacy in patients.  
In addition to secondary EGFR mutations, amplification of MET has also been 
described. The p190 MET gene encodes the receptor for the hepatocyte growth factor (HGF) 
(Naldini L, et al. 1991; Giordano et al. 1989). MET is widely expressed on the surface of 
epithelial cancer cells, whereas HGF is mostly secreted by mesenchymal cells (Prat et al. 
1994). However, overexpression and/or trans-activation by other RTKs can also overcome 
the requirement for paracrine stimulation. Met-mediated signaling regulates cell migration, 
cell scattering and invasion of extracellular matrices in adult tissues (Toschi and Passi 2008) 
through the activation of several signal transduction cascades, such as PI3K, MAPK, STAT, 
WNT and NOTCH pathways. While in other tumors, missense mutations have been found 
(hereditary papillary cell carcinoma) (Olivero et al. 1999; Di Renzo et al. 2000), in the case of 
NSCLC multiple studies have identified MET amplification as the principal source of its 
oncogenic activation. Depending on the studies, frequency of amplification varies from 1.4 
to 21% (Onozato et al. 2009; Beau-Faller et al. 2008; Cappuzzo et al. 2009). In addition, 
several groups have now reported an intronic splice variant of the MET gene that skips exon 
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14 in approximately 2-3% of Japanese patients with NSCLC (Onozato et al. 2009; Kong-
Beltran at al. 2006). Functional studies indicated that MET amplification is not only 
sufficient to drive tumorigenesis but also increases the metastatic potential on NSCLC cells. 
In particular, amplification of MET correlates with poor prognosis in surgically resected 
NSCLC patients (Cappuzzo et al 2009). More recently, MET amplification has been detected 
also in cancer patients that developed resistance to gefitinib or erlotinib.  In this case, MET-
induced resistance to EGFR inhibitors has been linked to activation of the PI3K pathway 
(Engelman et al. 2007).  
Among other RTKs over-expressed in NSCLC, there are PDGFR and FGFR. The 
PDGFR family includes the PDGFRα, PDGFRβ and Kit receptors (Zwick et al. 2001). The two 
receptors are activated by a ligand dimer consisting of PDGF-A and/or PDGF-B in three 
possible dimer conformations (αα, ββ and αβ) (Heldin et al. 1998). While cells of mesodermal 
origin such as fibroblast and smooth muscle cells, usually express PDGFR, it is also found in 
epithelial and endothelial cells (Ross et al. 1985; Shawver et al. 2002). Hence, not 
surprisingly, in 2007 PDGFRα was identified by biochemical, functional, and clinical 
analysis to be actively expressed in NSCLC tumors and cell lines (Rikova et al. 2007). Recent 
studies confirmed these initial findings and in addition also indicate that PDGFRA is 
amplified in lung squamous cell carcinoma (Heist & Engelman 2012). Similarly to EGFR, 
PDGFR stimulates signaling cascades mediated by phospholipase Cγ, PI3K, STAT5, and 
MAPK/SHP-2 (Rikova et al. 2007) and regulates cellular proliferation, differentiation, 
growth, motility and invasion. Interestingly, NSCLC cell lines and tumors harboring 
PDGFR-alpha amplification are sensitive to imatinib treatment, a PDGFR selective inhibitor 
used in the clinic for patients with CML (Rikova, et al. 2007).  
Deregulation of FGFR signaling caused by point mutations, elevated expression or 
different splicing forms has been identified in a variety of human tumors (Zwick, et al. 
2001). In the case of lung cancer, FGFR1 amplification has been identified in approximately 
20% of squamous cell cancers (Engelman 2012). Similarly to the case of other RTKs, 
inhibition of FGFR1 in cancer cell lines and in mouse models harboring FGFR1 amplification 
leads to growth inhibition and apoptosis (Heist and Engelman 2012).  
Interestingly despite their high similarities in their molecular structure and 
biochemical functions, distinct clinical features have been correlated with the activation of 
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different RTKs. Hence, in principle this suggests that distinct RTK mutations could 
contribute to lung cancer heterogeneity. In the last four years, my studies have been focused 
on trying to gain a better understanding of the molecular mechanisms behind signaling 
differences among RTKs frequently mutated in NSCLC and to determine whether 
phenotypic variations observed in tumors can be attributed to signaling variation among 
these oncogenes. 
Given the centrality of RTKs in my study in the next section I will first describe their 
molecular features, how they function and current principles underpinning their signaling 
specificities and commonalities. 
 
1.7 Receptor tyrosine kinases: structure and functions 
All RTKs possess a single trans-membrane domain separating the extra-cellular 
ligand binding portion from their intra-cellular tyrosine kinase region (Ullrich & 
Schlessinger 1990). All RTKs have a conserved kinase domain, composed of ~300 amino 
acids (Hubbard 1999). This domain is characterized by an amino-terminal lobe and a larger 
carboxy-terminal lobe. The cleft formed by the two lobes allows the transferring of the most 
distal phosphoryl group from an ATP molecule to a tyrosine hydroxyl group in the protein 
substrate.  
Sequencing of the human genome revealed the existence of 90 tyrosine kinases; 
among them, 58 are RTKs and 32 are non-RTKs (Manning et al. 2002; Robinson et al. 2000). 
Based on their similarity in the extra-cellular moiety, RTKs can then be classified into 20 
sub-families (van der Geer et al. 1994).  
Phylogenetic studies indicated that the first RTK likely arose from fusion of an 
epidermal growth factor (EGF)–like domain and a cytoplasmic tyrosine kinase, before the 
appearance of metazoans (King and Caroll 2001) (Figure 1.4). Subsequently, the number and 
diversity of RTK genes sharply increased during metazoan evolution, but remained 
exclusive to this subkingdom. The only exceptions are choanoflagellates, a type of flagellates 
that are morphologically similar to the choanocytes of certain sponges and are considered 
the closest living organisms to metazoans (Amit et al. 2007). The homology retention of 
RTKs during evolution is thought to be due to gene duplication and fusion events that give 
rise to divergent protein sequences characterized by distinct biological functions.  It has 
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been calculated that the frequency of gene duplication occurring in the course of evolution 
occurs at a background rate of 0.01 duplications per gene per million years (Lynch and 
Conery 2000).  
During evolution, gene duplication has expanded not only the number of RTKs, but 
also the components of their signaling pathways. Interestingly, upon duplication, highly 
connected proteins retained their interactions, creating networks rich in highly connected 
nodes (Rzhetsky and Gomez 2001; Pastor-Satorras et al. 2003), for example, the PI3K and 
MAPK families. This redundancy in principle can explain robustness, plasticity and 
contingency of signaling networks activated by RTKs, and at the same time suggests a 
certain degree of specificity in their biological activities.  
 
 Mechanism of activation of RTKs: Ligand binding, receptor dimerization and phosphorylation 
The mechanism of receptor kinase activation has been thoroughly characterized by 
structural and biochemical studies. It is now accepted that ligand binding induces a 
conformational change that stabilizes receptor dimerization leading to kinase activity and 
auto-phosphorylation of tyrosine residues present usually in their most terminal part (tail). 
Phosphorylation of tyrosines in the tail creates binding sites for effector proteins, hence 
leading to the activation a series of signaling pathways that mediate their biological effects 
(Zwick et al. 2001) (Figure 1.5).  
The structural diversity of ligands and receptors suggest various strategies for 
ligand-induced dimerization. There are four current models of dimerization (Lemmon and 
Schlessinger 2010). In the first model, the stable interaction between two receptors is 
permitted only in the presence of a bivalent ligand and an accessory molecule. The ligand in 
this case actively participates in the binding of the receptors. This is true in the case of 
activation of FGFRs, in which dimerization is achieved only in the presence of heparin and 
FGF (Spivak-Kroizman et al. 1994). In the second model, dimerization of the receptors is 
mediated exclusively through receptor-receptor interaction; the ligand in this case makes no 
direct contribution to the dimer interface, but allows for a change in the conformation that 
permits binding. EGFR can be activated through this mode. The binding of a number of 
ligands, including EGF, TGF-α and neuregulins (Olayioye et al. 2000), induce 
conformational changes in the extracellular region of EGFR, exposing the dimerization site 
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in domain II and allowing for the two EGFR monomers to interact (Burgess et al. 2003). 
Therefore, unlike FGFR, the dimerization of ErbB receptors is mediated entirely by the 
receptor, as each of the monomeric ligands binds to only one receptor on the opposite side 
to the surface where the two receptors interact to form a dimer. The third mode of receptor 
dimerization is entirely ligand-mediated and the two receptors are never in contact. This is 
the case of TrkA (NGF receptor) dimerization, in which two NGF molecules dimerize 
(Wehrman et al. 2007; Wiesmann et al. 1999; Lemmon and Schlessinger 2010). Lastly, as in 
the case of KIT, the ligand (stem cell factor) binds to the extracellular region of the receptor, 
mediating the interaction of two receptor molecules and allowing the two Ig-like domains in 
the proximity of the plasma membrane to interact (Liu et al. 2007; Yuzawa et al. 2007). In 
this case, the ligand allows for a conformational change, but also directly participates in the 
binding.   
Although the mechanism of activation by ligands is different, in all cases, 
dimerization leads to activation of RTKs. This is achieved through conformational changes 
in the intracellular moiety. As a consequence of dimerization, two RTKs are positioned in 
close proximity, allowing for trans-phosphorylation of critical tyrosine residues. 
Nonetheless, in the majority of RTKs, conformational changes are not sufficient to ensure 
full activity. Multiple cis- and trans- inhibitor mechanisms have in fact been shown to 
dampen RTK activity. In many instances, as in the case of MuSK, Flt3, KIT, and Ephs, the 
cytoplasmic juxta-membrane region of RTKs mediates cis-auto-inhibition. (Till et al. 2002; 
Griffith et al. 2004; Mol et al. 2004; Wybenga-Groot et al. 2001). Crystal structure studies in 
fact showed that the juxta-membrane region forms a helical structure, which interacts with 
the N-lobe of the kinase domain and prevents the DFG sequence in the activation loop to be 
positioned in the proximity of ATP and substrate. In other cases, auto-inhibition is provided 
by the C-terminal sequence. For instance, Tie2 C-terminal tail blocks substrate access by 
interacting with the active site of the  RTK (Niu et al. 2002; Shewchuk et al. 2000). In general, 
trans-phosphorylation of tyrosines in the activation loop, in the juxta-membrane segment, 
and/or in the C-terminal region, has been shown to relieve this inhibitory mechanism, 
allowing for full enzymatic activity.  
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 RTKs recruitment and activation of downstream signaling 
Auto-phosphorylation of RTKs not only primarily serves to enhance the catalytic 
activity after ligand binding, but also provides a docking site for the recruitment and 
activation of downstream signaling molecules (Ullrich and Schlessinger 1990). Enhancing 
the catalytic activity of RTKs by the first phosphorylation allows for phosphorylation of 
other tyrosine residues that recruit cytoplasmic signaling molecules containing Src 
homology-2 (SH2) and phosphotyrosine-binding (PTB) domains (Pawson 2004; Schlessinger 
and Lemmon 2003). Then, FGFR receptor substrate2 (FRS2), the insulin receptor substrate-1 
(IRS1) and the Grb2-associated binder (Gab1), work as scaffold proteins for the recruitment 
of other signaling components (Schlessinger 2000). 
Specificity in the binding of PTB and SH2 containing proteins to certain tyrosines is 
ensured by the amino acid sequences surrounding the phospho-acceptor site (Songyang and 
Cantley 2004). In the past, peptide library screens have been performed for the generation of 
quantitative SH2 interaction networks for certain RTKs (Songyang and Cantley 2004). In 
2009, the structure of an SH2 domain bound to a phosphorylated RTK was reported (Bae et 
al. 2009). This study corroborates previous findings and provides more detailed insight into 
SH2 binding specificity. In addition, based on crystallographic evidence, it appears that the 
four residues downstream of the phosphorylated tyrosine, a secondary binding site on the 
SH2 domain has also been shown to play a role (Bae et al. 2009). As for other tyrosine 
kinases, activation of RTK downstream signaling can also be triggered by the direct 
phosphorylation of substrates. This is the case for example for PLC-gamma and GAB1. 
 
 Functional differences among RTKs 
At first glance all the RTKs appear to be highly similar. As mentioned, all possess a 
highly homologous tyrosine-kinase domain, they activate almost the same signaling 
pathways (i.e., PI3K, MAPK, PLC gamma), and they all regulate very similar cellular 
functions (i.e., growth, motility, differentiation). However, several lines of evidence 
indicated specificity in their biological activities and functions (i.e., mesenchymal 
phenotype, sensitivity to selective RTK inhibitors). Knockout experiments in mice showed 
for example that EGFR is an essential gene, as its deletion results in embryonic lethality due 
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to compromised development of epithelial tissues in several organs, including skin, lung 
and gastrointestinal tract (Threadgill et al. 1995; Miettinen et al. 1995; Siblia & Wagner 1995). 
In contrast, although MET and PDGFR have also been shown to be essential for early mouse 
development; their deletion is lethal, in the first case due to abnormal placental 
development (Uehara 1995; Soriano 1994), and in the second case due to renal and 
hematological abnormalities (Schatteman 1992; Orr-Urtreger 1992). Interestingly, in contrast 
to EGFR deficient mice, knocking-out specific EGFR ligands (EGF, TGF-alpha, amphiregulin 
and heparin-binding EGF) showed tissue-restricted phenotypes, suggesting ligand/receptor 
interaction plays a role in mediating the observed phenotypic variation (Luetteke et al. 1999; 
Luetteke et al. 1993; Iwamoto et al. 2003; Jackson et al. 2003). The importance of ligands in 
dictating RTKs biological diversity is exemplified by fibroblast growth factor receptor 
(FGFR). There are over 48 different isoforms of FGFRs produced by alternative splicing in 
the extracellular domain of the four FGFR genes (Duchesne et al 2006). Each of these 
isoforms has selective affinity to fibroblast growth factors, which are the largest family of 
growth factor ligands, comprising 22 members (Ornitz and Itoh 2001). In principle, these 
studies suggest that temporal and spatial control of RTKs activity by availability of different 
ligands is an important feature regulating their function and specificity.  
Ligand specificity can also explain differences among RTKs observed in vitro, where 
clearly the availability of growth factors is not limiting. In this case, different 
ligand/receptor affinities and intrinsic chemical and physical properties of ligands such as 
resistance to acidification, can lead to sustained activation of RTKs in different cellular 
compartments. This is the case for example of EGFR stimulation by EGF or TGF-alpha. The 
latter has an increased binding affinity and is resistant to acidification (Kramer et al. 1994). 
As a consequence, while EGF can induce a transient stimulation that is limited to activation 
of EGFR at the plasma-membrane, stimulation of cells with TGF-alpha results in prolonged 
activation of EGFR, even in multi-vesicular bodies, characterized by a low pH (Lenferink et 
al. 1998). 
However other studies have clearly indicated that differences in interaction with 
signaling effectors play an equally important role in ensuring signaling specificity among 
RTKs. It has been shown for example that variation in intracellular binding sequences 
results in qualitative activation of signal transduction modules. This is the case, for example, 
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for insulin receptor (IR) and EGFR. While the first possesses four binding sites for PI3K, the 
second possess none. Hence, IR can directly activate PI3K, while EGFR can induce 
activation of PI3K only indirectly, either through the recruitment of GAB family members or 
by trans-phosphorylating Her2 and Her3. In a similar fashion, negative regulators can 
differentially impact RTK-mediated signaling by binding to RTKs with different strength 
(e.g., MIG6) (Segatto et al 2011). 
 
 Specificity of signaling: substrate specificity 
Protein phosphorylation is one of the most fundamental mechanisms for signal 
transduction. Consequently, protein kinases are among the largest classes of human genes, 
encompassing ≈600 members (Mannin 2002). In the case of soluble kinases, the specificity of 
signal transduction clearly cannot depend on ligands, but has been shown to depend on the 
ability of each kinase to precisely phosphorylate particular sites on specific substrate 
proteins. The specificity of phosphorylation is in this case determined by at least two major 
elements: peptide specificity and regulated co-localization of substrate/kinase (Faux and 
Scott 1996; Kreegipuu et al. 1998; Oancea and Meyer 1998; Newton 2001; Parker and 
Parkinson 2001). 
Peptide specificity describes the preference of a kinase for particular amino acids 
surrounding the phosphorylation site. Kinases typically discriminate well in their substrates 
preferences. Studies conducted in the late 1980s and early 1990s have generated “consensus 
motifs” and classification of serine and threonine kinases into three classes: basophilic 
kinases (PKA, PKC), which favor basic residues around the phosphorylation site; and 
acidophilic kinases (CKII) and proline-directed kinases (CDKs and MAPKs), which require 
a proline residue immediately C-terminal to the phosphorylation site (Kreegipuu et al. 
1998). This likely indicates the spatial structure of the peptide chain around the 
phosphorylatable group and electrostatic forces that are important for the substrate 
specificity of many protein kinases. At that time, specialized graph representations were 
also developed. In a typical “sequence logo” the phosphorylation site is at the center (P0), 
residues N-terminal to it are on the left and at the C-terminal are on the right. Each position 
is represented by a stack of letters, each representing an amino acid code. The higher the 
letter, the higher the selectivity (Shneider and Stephens 1990). Selectivity is usually 
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determined as the difference between the distribution of residues at that position and the 
proteome in general. Letters are generally also color coded to indicate physico-chemical 
properties; for example, blue for basic, red for acidic, black for hydrophobic. 
In the mid-1990s, in addition to “substrate specificity” the concept of “substrate 
recruitment” was introduced.  Studies have shown that PTK specificity also depends on the 
proximity and availability of the substrate. Clearly this departs from the view that cells are 
freely diffusible systems in which enzymes and substrates are free to float around. Efficient 
and specific peptide substrates for some PTKs with Km in the mid micro molar range have 
been identified (Shu et al. 2005). This implies that during evolution, efficient 
phosphorylation of any given substrate has been selected either by optimizing sequences 
surrounding the phosphorylation site and/or by increasing the frequency of encounters of a 
mediocre substrate with a kinase. Auto-phosphorylation sites are an extreme case, in which 
surrounding sequences are not “good” substrates per se. Yet, the fact that these are 
“mediocre” sequences suggests that even strong recruitment is not sufficient to compensate 
for very low phosphorylation rate. Therefore, because of the cooperation of recruitment and 
peptide specificity in creating phosphorylation specificity, it is virtually impossible to 
predict a priori which of the two has been selected during evolution. 
While people agree that substrate specificity plays a role in serine (Ser) and 
threonine (Thr) kinases, early studies based on p60SRC auto-phosphorylation site peptides 
and angiotensin suggested that protein tyrosine kinases are much more promiscuous and 
have very low substrate specificity (Cheng et al. 1993). However, contrary evidence has 
accumulated over the years, suggesting this assumption needs to be re-examined.  
In 1988, Sahal et al. hypothesized substrate specificity differences among RTKs in a 
seminal study on differential phosphorylation of tyrosine-containing polymers by insulin 
receptor and IGF-1R (Sahal et al. 1988). Those initial findings were subsequent by supported 
by studies from Todd Miller and colleagues and by Cantley and colleagues (Xu et al. 1995; 
Songyang et al. 1994a). Miller’s group compared the capability of purified intracellular 
domain of IR and IGF1R to phosphorylate a series of peptides that reproduced the major 
phosphorylation sites found in these receptors. They found that while both can highly 
phosphorylate peptides containing the YMXM or YXXM consensus, only IGF1R was less 
dependent on the presence of methionine residues C-terminal to the tyrosine site. As 
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opposed to IR, IGF1R in fact can efficiently phosphorylate a peptide (YVNI) corresponding 
to the IRS-1 Y895 site. Cantley et al. instead used a degenerate peptide library to show that 
each residue surrounding the tyrosine is an important determinant of substrate specificity 
for PTKs (Songyang et al. 1994a). By using this novel technique, they were able to compare 
substrate specificity among Fes, SRC, LCK, ABL, EGFR, PDGFR, FGFR and IR. They showed 
that residues at least four amino acids upstream and four amino acids downstream of the 
phospho-acceptor site can contribute to substrate specificity. In addition, they found that 
most PTKs selected peptides with D or E residues N-terminal to the tyrosine residues. 
Interestingly, while cytosolic TKs selected for substrates with I or V at position -1 and D, A 
or G at position +1, RTKs selected substrates with a D at position -1 and large hydrophobic 
amino acids at position +1. All selected hydrophobic amino acid at position +3. 
Last year, Lipari’s laboratory provided further evidence by assaying differences in 
substrate specificity among 81 tyrosine kinases with three different substrates (Blouin et al. 
2011). They found that while the JAK1 peptide (CAGAGAIETDKEYYTVKD) was highly 
promiscuous for many PTKs, all SRC family kinases efficiently phosphorylated the CDK1 
peptide (KIGEGTYGVVYK) and RTKs greatly favored the IRS1 peptide 
(CKKSRGDYMTMQIG). Of note, 65–70% of all the phosphorylatable residues were 
predicted to be on the surface of the protein. 
In addition to the above mentioned studies, bioinformatic approaches have also been 
implemented to identify kinase consensus sites. For example, Kreegipuuet and collaborators 
analyzed 14849 Ser, 11095 Thr and 6535 Tyr residues in 406 distinct proteins by 34 different 
kinases (Kreegipuuet al. 1999). One interesting observation that emerged from these studies 
was that the majority of Ser/Thr kinases have a preference for serine residues, with the 
number of discovered threonine phosphorylation sites being in most cases 3–10 times less 
than the number of serine sites. This cannot be explained by different natural occurrence of 
these amino acids since the ratio of serine and threonine content in proteins is 1.3:1 as 
calculated from sequence data for more than 60000 different proteins (SwissProt database 
http://www.sciencedirect.com/science/article/pii/S0014579398005031-BIB9#BIB9). 
Similar to previous studies, these observations confirmed the importance of amino acids 
between positions −4 and +4 around the phosphorylation site. This statistical analysis also 
indicated that most of the Ser/Thr protein kinases can be divided into three classes, 
 35 
including basophilic (e.g. PKA, PKC, CaM-II kinase), acidophilic (e.g. casein kinases I and II), 
and proline-directed protein kinases (e.g. cyclin-dependent kinases, MAP kinases), and 
further, that most of the analyzed tyrosine kinases are acidophilic. Interestingly, 
comparative analysis of protein secondary structure also suggests its influence to be much 
weaker respect to the effects of the peptide primary structure. Overall, the recent findings 
support the previous observations, suggesting that substrate specificity is important in 
mediating biological differences among kinases.  
Additional evidence that catalytic specificity is critical for functional differences 
among RTKS is supported by studies of RTKS oncogenic variants. In the case of RET 
receptor, a germ-line mutation affecting the catalytic core results in the autosomal cancer 
syndrome MEN2B (multiple endocrine neoplasia type 2-B) (Eng 1996). In the mutated form 
a methionine in position 918 is changed into a threonine residue in the catalytic domain. As 
a consequence while WT RET phosphorylates the optimal peptide AEEEEYFELVAKKK, the 
mutant RET in addition to this peptide now also phosphorylates optimal substrates for SRC 
and ABL and mediates the activation of pathway normally mediated by SH-2 containing 
PTKS and protein containing SH2 of the group I. Similarly we recently observed differences 
in substrates specificity among wild type and mutant EGFR.  
The availability of crystal structures for the majority of kinases has provided 
molecular insights on substrate specificity among protein tyrosine kinases. These studies 
revealed that PTK specificity is dictated by multiple factors, including the amino acid 
sequence surrounding the phosphorylation site, long-range interactions with other motifs 
and surfaces of the substrate, and the recruitment of substrates by domains other than the 
kinase catalytic domain. 
The protein kinase domain is highly conserved among both tyrosine and 
serine/threonine kinases. As mentioned previously, it contains an N-terminal lobe involved 
in ATP binding and a C-terminal lobe that is thought to be involved in protein substrate 
recognition. However, with the exception of IRK, there has been limited information until 
very recently about how most PTKs recognize tyrosine-containing peptide substrates. This 
is mainly due to challenges in the crystallization of PTK–peptide substrate complexes 
because of the generally low affinity of this interaction. Several lines of evidence have 
suggested that the transition state for PTK reactions is dissociative (Kim and Cole 1997; Kim 
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and Cole 1998; Ablooglu et al. 2000). In a dissociative (as opposed to an associative) 
transition state, there is little bond formation between the tyrosine (substrate) on the peptide 
and the attacked phosphorus before substantial departure of the ADP. For instance, a bi-
substrate analog of a physiological peptide sequence based on the insulin receptor substrate 
1 (IRS-1) Tyr727-containing region (i.e., IRS727–ATP), was designed and synthesized as a 
selective and potent inhibitor of IRK in which ATPγS is linked to a tyrosine-mimic-
containing peptide via an acetyl spacer (Parang et al. 2001).  IRS727–ATP proved to be a 
useful tool for the X-ray crystallographic analysis of IRK bound to substrate. In addition, the 
IRK co-crystal structure with the IRS727–ATP bi-substrate analog showed the expected 
interactions of nucleotide and peptide moieties with the appropriate kinase binding sites 
(Parang et al. 2001). Also the IRK co-crystal structure showed that the P+1 and P+3 
methionine residues in the peptide were positioned in shallow hydrophobic pockets on the 
surface of the C-terminal kinase lobe and formed an interaction with the activation loop of 
the kinase. The encouraging results with the IRK co-crystal structure led to the further 
synthesis and study of several other bi-substrate analogs targeted against different 
serine/threonine and tyrosine protein kinases (Shen and Cole 2003; Hines and Cole 2004; 
Hines et al. 2005; Cheng et al. 2006; Levinson et al. 2006; Zhang et al. 2006). Despite limited 
sequence homology, a comparison of the primary structure of the peptide moieties of the bi-
substrate analogs that crystallized with the IRK, Abl and EGFR kinases and the structure of 
the enzyme binding pockets reveals the importance of non-polar and hydrophobic 
interactions at the P + 1 and P + 3 positions, suggesting a model in which hydrophobic 
interactions predominate in the binding of peptides substrate to tyrosine kinases.  
Yet despite the accumulations of all these evidences, in the majority of cases 
substrate preferences are not considered as a determinant of RTKs specificity. 
 
1.8 Beyond the genetic landscape of lung cancer: epigenetic regulation and 
microRNA-mediated regulation of lung cancer 
I would like to end this chapter by mentioning that in addition to genetic 
aberrations; recently it has been observed that other molecular mechanisms can modify gene 
expression without any changes in DNA sequence. In particular DNA hyper-methylation 
has been proposed to play a role in lung tumorigenesis (Helman et al. 2012). Increased DNA 
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methylation in a normally un-methylated promoter region of a gene usually results in 
silencing of gene transcription and is therefore viewed as an alternative route for the 
inactivation of TSGs. In lung cancer, many genes have been found to be silenced by 
promoter hypermethylation (Rauch et al. 2008; Pfeifer and Rauch 2009). Usually, they are 
involved in tumor suppression, tissue invasion, DNA repair, detoxification of tobacco 
carcinogens, and differentiation.  
miRNAs are a recently identified class of non–protein encoding small RNAs present 
in the genomes of plants and animals (He and Hannon 2004). Ranging in size from 20 to 25 
nucleotides, miRNAs are small RNA molecules that are capable of regulating gene 
expression by either direct cleavage of a targeted mRNA or inhibiting translation by 
interacting with the 3′ untranslated region (UTR) of a target mRNAs (Ambros 2003; Bartel. 
2004; Lai 2003; He and Hannon 2004). One of the most widely studied miRNAs in lung 
cancer is the lethal-7 (let-7) miRNA family (Reinhart et al. 2002; Osada and Takahashi 2010). 
Functioning as a tumor suppressor, let-7 has been shown to regulate NRAS, KRAS, and 
HMGA2 via binding to their respective 3′ UTRs. It is frequently under-expressed in lung 
tumors, particularly NSCLC, compared with normal lung, and decreased expression has 
also been associated with poor prognosis (Takamizawa et al. 2004). Induction of let-7 
miRNA expression has been found to inhibit growth in vitro and reduce tumor development 
in a murine model of lung cancer (Esquela-Kerscher et al. 2008; Kumar et al. 2008; Trang et 
al. 2010). In addition to let-7, other miRNAs with suggested tumor-suppressing effects in 
lung cancer include miR-126, miR-29a/b/c, miR-1 (Leidinger  et al. 2011), and recently, miR-
128b was reported to be a direct regulator of EGFR with frequent LOH occurring in NSCLC 
cell lines (Weiss et al. 2008). Oncogenic miRNAs found to be over-expressed in lung cancer 
include the miR-17-92 cluster miR-205, miR-21, and miR-155 (Leidinger et al. 2011).  In 
collaboration with Dr. Greg Hannon’s laboratory at CSHL and Dr. Stiles at Cornell Weill 
Medical Center our laboratory has recently identified novel mir-RNA associated with 
increased metastatic spread.  
 
1.9 Conclusions 
Genetic and epigenetic mechanisms underlying lung cancer development and 
progression continue to emerge. Over the past decade, research has been spearheaded by 
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the development of whole-genome microarray technology, allowing the simultaneous 
analysis of expression, copy number, and SNPs across thousands of genes. In lung cancer, 
these studies have led to development of a new taxonomy not based on the site of 
occurrence of tumors and histological appearance but on genetic lesions. In this chapter, I 
outlined some of the more significant molecular alterations known to be involved in the 
initiation and/or progression of lung cancer.  
The picture that emerges from these studies is the enormous complexity of NSCLC. 
It has now become clear that distinct mutations occur in different subtypes of NSCLC and 
that tumor progression can result as a consequence of activation of multiple routes. Even 
when driven by mutations in the same genes, different NSCLC subtypes can present 
varying patterns of gene mutations. Examples are EGFR, KRAS, ALK, and β-catenin that are 
clearly predominantly mutated in lung adenocarcinomas, while p53 has a much higher 
mutation frequency in squamous cell carcinoma. In the case of KRAS, interestingly, 
although overall the mutation frequency of KRAS is predominant in adenocarcinoma, exon 
2 mutations are instead more frequent in squamous cell tumors than in the other subtypes. 
Similarly, BRAF and PIK3CA have similar mutation frequencies in the different lung cancer 
subtypes: exon 20 of PIK3CA is mutated more frequently in AD than SQ, and exon 11 of 
BRAF is mutated more frequently in SQ than AD. Furthermore, non-V600E BRAF mutations 
are observed more frequently in NSCLC than in melanoma.  
Moreover, within subtypes, certain categories of gene mutations can be even further 
classified on the basis of histopathologic characteristics. For example, KRAS mutations are 
strongly associated with mucinous BAC subtypes of adenocarcinomas, whereas EGFR and 
p53 mutations are associated with non-mucinous BACs. Therefore, a more precise 
understanding of the biology behind specific genetic alterations will certainly be 
instrumental in increasing opportunities for targeted therapies.  
In this regard we were particularly fascinated by the frequent occurrence of 
mutations within RTKs. Despite their structural and functional similarities, distinct 
oncogenic RTKs mutations have been correlated with different tumor characteristics 
suggesting differences in their signaling pathways.  
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Figure 1.1. Pie charts representing the distribution of lung cancer based on histological type. Lung cancer has 
traditionally been subdivided into two major types: small cell lung carcinoma and NSCLC, the latter accounting for 
almost 80% of all cases (NCI 2012). NSCLC is further classified into epidermoid/squamous (29%), 
adenocarcinoma/bronchioalveolar (35%), and large cell (9%) (Travis et al. 2004). 
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Figure 1.2. Timeline of seminal hypotheses, research discoveries, and research initiatives that have led to an 
improved cancer genome in the past 100 years. Obtained from Devita et al. 2011. 
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Figure 1.3. The diagram illustrates signaling networks that are altered in NSCLC. Positions of signaling molecules are ordered 
from top to bottom to denote upstream-to-downstream signaling cascades with their respective cellular functions. Commonly 
mutated genes in NSCLC are denoted with a star (*). Therapeutic agents developed against specific proteins in NSCLC are 
also indicated and their known therapy responses. In the boxes: D indicates availability of a drug (green box, current clinical 
therapy; yellow box, drugs in clinical trials; gray box, investigated in other cancer types or other specific NSCLC cell lines). 
Treatment responses associated with mutations are indicated by S (sensitive) or R (resistant). Activation (arrow) or inhibition 
(tee) are indicated for each pathway component. 
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Figure 1.4. The evolution and expansion of RTK signaling. The number of kinases and MAPKs in several representative 
species is listed for vertebrates and for key invertebrate phyla, or other eukaryotes with whole-genome data shown in 
phylogenetic tree. Figure obtained from Amit et al. 2007. The number of CTKs (cytoplasmic tyrosine kinases) and RTKs were 
derived from published total tyrosine kinase counts, except where marked and noted below, as were counts of EGFRs/ErbB 
(EGFRs) and MAPKs. The ratio of vertebrate to average invertebrate counts of each protein category was calculated, as 
weighted for total proteome size. 
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Figure 1.5.  RTKs as nodes in complex signaling networks. All RTKs have a similar molecular architecture, with ligand-
binding domains in the extracellular region, a single transmembrane helix, and a cytoplasmic region that contains the protein 
tyrosine kinase (TK) domain plus additional carboxy (C-) terminal and juxtamembrane regulatory regions. They have a highly 
conserved kinase domain and variable ligand binding domains. Receptor tyrosine kinases contain multiple tyrosines and are 
inactive in the monomer state.  Represented in the above diagram is the EGFR subfamily. Binding of signal molecules, such as 
EGF, causes 2 monomers to form a dimer. ATP donates a phosphate to each of the tyrosines. Distinct RTKs have different 
docking consensus sites for several effector proteins. Relay proteins bind to the phosphorylated tyrosines, and trigger 
different cellular responses. As a result, a highly specific signaling network is established. However, the different mechanisms 
responsible for the diverse biological outputs observed by the different RTKs are still uncertain.  
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Synopsis 
Since their initial discovery, increasing amounts of data implicated the deregulation 
and malfunctioning of RTKs in a variety of diseases (Gschewind 2004), including lung 
cancer (Ding et al. 2008). Therefore, a detailed knowledge of RTK biology is crucial for 
understanding tumorigenesis and developing effective target therapies.  
At first glance, all RTKs appear to be highly similar. As mentioned in the previous 
section, all possess a highly homologous tyrosine-kinase domain, activate in essence the 
same signaling pathways (i.e., PI3K, MAPK, and PLC gamma), and regulate very similar 
cell functions (i.e., growth, motility, and differentiation). However, several experiments 
have indicated specificity in the biological activities of RTKs (i.e., mesenchymal phenotype 
and sensitivity to selective RTK inhibitors). In 1995, Soriano et al. utilized as an experimental 
system normal mouse mammary gland cells and compared the activity of different RTKs in 
inducing branching-like structures in a 3D gel composed of collagen and laminin. The only 
RTK capable of forming branching duct-like structures was c-MET (Soriano et al. 1995)  
Functionally, differences among RTKs have been also suggested in vivo. In the case 
of NSCLC, for example, the activation of PDGFR-alpha leads to the acquisition of 
mesenchymal-like features, increased metastatic potential, and has been associated with 
poor tumor prognosis (Gotzmann et al. 2006). In addition, overexpression of PDGFR-alpha 
has also been observed in cells that have become resistant to erlotinib treatment (Pao et al. 
2004). For this reason, I primarily focused on characterizing PDGFR-alpha kinase (referred 
to as PDGFR). 
While it is now widely accepted that distinct RTKs have specific biological function, 
the molecular mechanisms behind their specificity are still a matter of debate. As part of 
current theories proposed to explain the diverse biological outputs of RTKs, it has been 
suggested that the specificity of RTKs depends on temporal and spatial control of enzyme 
activity as well as on the selective interaction of RTKs with defined effector molecules. 
Alternatively, we hypothesized that biological differences among RTKs can be explained by 
distinct substrate specificity.  
To better understand differences among RTKs and in order to provide experimental 
evidence in support of our hypothesis, during the course of my thesis studies, I utilized a 
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multifaceted approach that included biochemical (Chapter 2.1), phospho-proteomic 
(Appendix 1), and functional genomic (Appendix 2) methodologies. 
We found that indeed EGFR and PDGFR as well other RTKs are characterized by 
distinct substrate specificity (Chapter 2). By using bioinformatics tools we then identified 
SOCS3 as one protein differentially phosphorylated both in vitro and in vivo by these two 
RTKs (Chapter 2). The phosphorylation of SOCS3 results in ubiquitin-proteasomal mediated 
degradation of SOCS3 and in a sustained IL-6 mediated signaling (Chapter 3). As a result, 
cells acquire mesenchymal and pro-metastatic features (Chapter 4).  
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Chapter 2: Oncogenic RTKs have distinct substrate preferences 
2.1 Summary 
At first glance, all RTKs appear to be highly similar. However, several experiments 
have indicated specificity in the biological activities of RTKs. As part of current theories 
proposed to explain the diverse biological outputs of RTKs, it has been suggested that the 
specificity of RTKs depends on temporal and spatial control of enzyme activity as well as on 
the selective interaction of RTKs with defined effector molecules. As an alternative, we 
hypothesized that biological differences among RTKs can be explained by distinct substrate 
specificity. We found that EGFR and PDGFR as well other RTKs are characterized by 
distinct substrate specificity. Interestingly RTKs with activity that leads to EMT and 
erlotinib resistance have similar substrate preferences. 
 
2.2 Highlights 
 PDGFR and EGFR are characterized by defined substrate specificities 
 RTKs with activity that leads to EMT and erlotinib resistance have similar substrate 
preferences 
 
2.3 Introduction 
It is now widely accepted that, despite their high homology, RTKs are characterized 
by distinct biological functions. We hypothesized that distinct substrate specificity among 
RTKs can explain their diverse biological outputs.  
In the past few years, several techniques such as mass spectrometry (MS), protein 
chips, computational algorithms, and live cell imaging have been employed to identify and 
study kinase–substrate relationships. These have provided groundbreaking information 
regarding differences in signaling pathways activated by different RTKs. For instance, MS 
has been extensively applied to identify proteins that are phosphorylated by a given 
tyrosine kinase. Phosphoproteomic studies of Src, Her2/neu, EGFR, and insulin receptor 
have recently been reported (Blagoev et al. 2004; Ibarrola et al. 2004; Kratchmarova et al. 
2005; Zhang et al. 2005; Bose et al. 2006; Qiao et al. 2006; Schmelzle et al. 2006; Wang et al. 
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2006). Furthermore, substrates of the Bcr-Abl fusion protein have also been inferred from 
proteomic studies with Imatinib (Gleevec®), a Bcr-Abl-directed small-molecule kinase 
inhibitor  (Goss et al. 2006; Liang et al. 2006). Although MS based methodologies can lead to 
the rapid isolation and identification of phosphorylated proteins in an unbiased fashion, 
they are incapable of distinguishing between proteins that are direct substrates and those 
that are phosphorylated by downstream kinases. To improve the temporal resolution of MS 
experiments, methods based on stable isotope labeling have been developed for quantitative 
analysis prior to MS use. In this setting, proteins are labeled with different stable isotopes 
(Silac) or chemical labels (iTRAQ), either during cell culture or after cells have been lysed 
(reviewed in Johnson and White, 2012). Although in principle, the use of chemical 
complementation has the potential to provide temporal and spatial connection to validate 
the kinase–substrate linkage, this technology has not been developed to allow for sufficient 
in-depth analysis (Shogren-Knaak et al. 2001; Qiao et al. 2006).  
As an alternative, Cantley and colleagues developed a blueprint that provided a 
major breakthrough in understanding the peptide specificity of PTKs (Songyang et al. 
1994a). Their method is based on the phosphorylation of degenerate peptide libraries. The 
kinase of interest is incubated in solution with a very large number of peptides, all 
containing a single fixed tyrosine within a degenerate peptide sequence made up of all 
possible amino acids. Only those peptides that contain favorable amino acids surround the 
fixed phospho-acceptor site and are phosphorylated by the kinase. In the first iteration of 
this method, the phosphorylated peptides are separated from the bulk of non-
phosphorylated peptides and sequenced by Edman degradation. The affinity of the kinase 
for any amino acid at each position is then determined by comparing the ratio of amino acid 
present at each position in the phosphorylated peptides versus the starting peptide library 
mixture.  
In practice, the technique Cantley’s lab developed has proven very challenging and 
time consuming, mainly due to difficulties in the separation of the phosphorylated peptides 
from the non-phosphorylated peptide background. One way around these problems 
involves the use of peptides that are immobilized on a solid support. The optimal motif 
phosphorylated by the kinase in this case can be easily determined by incubating the 
immobilized peptides with the kinase of interest in the presence of [32P] ATP. The amount 
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of radioactivity incorporated into the solid support at each position in the array indicates 
whether the motifs are optimal. Yet this technique also has several limitations because of 
high background signals caused by non-specific association between radio-labeled ATP on 
the support membrane. Non-specific interaction of the kinase with the membrane can also 
result in not homogenous kinase distribution.  
To overcome to these hurdles, Cantley and colleagues recently optimized a 
methodology that uses the best aspects of both the solution-phase and the solid-support 
approaches (Hutti et al. 2004). In this case a library containing 198 separate degenerate 
peptide mixtures is used, each mixture containing a fixed serine or threonine residue and a 
second single fixed amino acid in any one of nine flanking positions. The second fixed 
position includes any one of the twenty naturally occurring amino acids as well as phospho-
threonine and phosphotyrosine. The remaining flanking positions contain a degenerate 
mixture of all the amino acids. Importantly, all of the libraries contain an N-terminal biotin 
tag, so that the kinase reaction can be performed in solution, after which the peptides can be 
spotted and captured onto avidin-coated membrane (Hutti et al. 2004). The use of solution-
phase phosphorylation eliminates many of the artifacts seen with immobilized substrates, 
and the solid-phase peptide capture and quantification excludes the requirement for Edman 
sequencing. This in turn eliminates the problem of phosphopeptide purification and allows 
for phosphorylated amino acids to be included in the motif determination. Using this 
approach, Turk and colleagues were recently able to obtain and/or confirm the 
phosphorylation motifs for PKC, PKD, and type II TGF receptor kinase, as well as to 
identify a new motif for the proto-oncogene kinase Pim2 (Turk et al. 2006). 
By utilizing a similar technology, we were able to demonstrate that RTKs are 
characterized by profound differences in their substrate specificity, hence suggesting the 
intriguing hypothesis that substrate specificities can underpin the diversity in the biological 
outputs of RTKs.  
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RESULTS 
2.4 Peptide library design and kinase assay optimization 
In order to identifying optimal phosphorylation consensus motifs for PDGFR and 
EGFR, I used a positional scanning peptide library technique similar to the approach 
described by Turk and colleagues (Turk et al. 2006). This biochemical approach allowed up-
front identification of potential direct substrates without the need to perform kinase assays 
on individual substrates.  
Specifically, a library composed of 198 separate synthetic peptides was synthesized 
by Primm, Biotech Inc. (See Figure 2.1 for more details). The peptides were each nine amino 
acid long and contained a central fixed tyrosine residue flanked on both sides by a mixture 
of degenerate amino acids at positions -1,-2,-3,-4,-5 and +1,+2,+3,+4. The peptides also 
contained a second single fixed amino acid in any one of nine flanking positions. Degenerate 
positions were prepared by coupling mixtures of the twenty naturally occurring amino 
acids and the second fixed position included any one of the twenty naturally occurring 
amino acids. Each peptide contained an NH2-terminal biotin tag separated from the rest by 
three glycine (spacer) residues (Figure 2.1). Each peptide mixture was synthesized on a scale 
of 5 mg. The crude peptide mixtures were dissolved in DMSO to achieve an approximate 
concentration of 25 mM. To perform the kinase assays, a working 0.5 mM aqueous peptide 
solution was prepared by rapidly diluting the 25mM-stock solution with 50 mM HEPES, pH 
7.4.  
The enzymes used in the kinase assays were generated as GST-tagged recombinant 
proteins in insect cells (Baculo virus). This system allows for the purification of the protein 
under non-denaturing conditions by binding its substrate to glutathione and following with 
elution. More precisely, for our studies we employed only the intracellular domain of each 
RTK. In each case, glutathione purification yielded proteins that were over 80% pure by 
Coomassie blue-stained SDS-PAGE gel. The identity of each kinase was sequence-verified 
by digesting with trypsin followed by LS-MS/MS. The MS/MS data verified PDGFR 
identity (amino acids 550-1089) from 55 peptides that covered 50% of the amino acid 
sequence of the recombinant protein. In the case of EGFR (amino acids 668-1210), identity 
was determined from 23 peptides that covered 29% of the amino acid sequence of the 
recombinant protein. 
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It has been shown that RTKs have distinguishable preferences for Mn2+. Therefore, 
as a first step I determined the optimal kinase reaction buffer composition by trial and error. 
In particular I established that the optimal buffer composition must include 20 mM MOPS 
(pH7.0), 1 mM EGTA, 0.1% Triton X-100, 10 mM MnCl2, 0.1 mM Na3VO4, 0.5 mM NaF3, 
1mg/ml BSA, and 0.5% glycerol. Figure 2.2.A demonstrates that in these conditions both 
EGFR and PDGFR have very similar kinase activities, as measured by auto-
phosphorylation. All assays were performed at a saturating concentration of ATP, so that 
ATP was not a limiting component of the reaction. Specifically, the concentration of ATP 
corresponded to approximately five times the predicted Km using an optimal peptide as 
substrate (e.g., DNDYINA).  
To determine the optimal kinase activity and substrate concentration for the kinase 
assay, I performed a titration experiment in which decreasing amounts of kinase and 
decreasing concentrations of a peptide containing a specific tyrosine were assayed (Figure 
2.2.B). The kinase reactions were incubated at 30ºC for 30 minutes. Previous experiments 
indicated that, at this time point, our range of peptide and enzyme concentrations produces 
a linear reaction. After completion, 5μl from each reaction were spotted onto streptavidin-
coated filter membranes (Promega SAM2 biotin capture membrane). Spots occupied an area 
of approximately 16 mm2; according to the manufacturer the membrane capacity for this 
area is 200 pmol. Membranes were washed three times with phosphoric acid and exposed to 
a phospho-imager screen overnight. Radioactive signals were detected using a Fujifilm FLA-
5100 instrument (Fuji Medical Systems USA, Inc.) and spot intensities were quantified using 
Multi-Gauge v2.3 software (Fuji Photo Film Co.). Based on good signal, a low signal-to-noise 
ratio, the linearity of the kinase reaction, and the binding capability of the membrane 
(100pM/10 sqmm), I decided to utilize approximately 10 ng of kinases per well and 100 
pmol of peptide.  
 
2.5 PGFR and EGFR are characterized by distinct substrate specificities 
Utilizing the aforementioned experimental conditions, I compared EGFR and 
PDGFR substrates specificities.   Individual kinase assays were performed for each of the 
peptides mixtures contained in the library by using a 96-well format and then spotting on a 
streptavidin membrane. As shown in Figure 2.3, I found that PDGFR and EGFR each have 
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optimal substrate specificities. These differences were highly reproducible as I was able to 
replicate the data shown in three independent experiments with similar pattern of 
phosphorylation.  
To validate the experiments, I super-imposed the sequences of known EGFR and 
PDGFR phosphorylation sites—such as the sites for GAB1, JAK1, or HER3 Y1022 
(EDMMDAEEYLVPQAFNI), HER3 Y1202 (ASNGPPKAEDEYVNEPL), HER4 Y1022 
(EDMMDAEEYLVPQAFNI), HER2 Y1023 (GDLVDAEEYLVPQQGFF), and HER2 
Y1248(TPTVAENPEYLGLDVPV)—with the matrixes obtained in my experiments.  In all 
cases, phosphorylation sites matched our predictions.  
One of the most striking results from our experiment was the profound differences 
among the phosphorylation patterns of EGFR and PDGFR (Figure 2.3). To better compare 
the observed qualitative differences, we transformed the intensity of signaling into a 
quantitative measurement, in collaboration with Gordon Assaf and Simon Knott from the 
Hannon Laboratory. Multi-Gauge v2.3 software was used to detect and quantify each 
phosphorylated spot on the peptide screens and produce a quantitative analysis of the data. 
Briefly, I used the ROI oval tool to set the quantitative region in mm2 so that it fit the shape 
of each spot. I set the control spots as background regions as a proxy for background 
intensity. The software provided a list of intensity units according to the amino acid 
position. Lastly, to calculate the measured areas, I subtracted the background intensity from 
the region intensity per unit area (I-B/mm2). The relative intensity of each spot was then 
transformed into a Z score: the mean intensity of all spots was subtracted from the intensity 
of individual spots, and the result was divided by the standard deviation of all spots. The Z 
scores were then sorted in ascending order. If a particular residue was favored, the Z-value 
was greater than 1.0; when the residue was disfavored, the Z-value was less than 1.0.  
To visualize the quantitative measurements, we utilized the Two Sample Logo (TSL), 
which is an MIT Open Source License web-based application (Crooks et al. 2004). Using this 
algorithm, residues can be plotted using various color schemes and shared residues can be 
added to the plot in order to visualize the motif itself. TSL also visually emphasizes the 
depleted residues as much as the enriched residues (Figure 2.4.A). In the graphical 
representation for each of the kinases, every stack of letters represents residues at a position 
in the substrate. In each stack, strongly favored residues are at the top and strongly 
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disfavored residues are at the bottom; residues that are neither strongly enriched nor 
depleted (i.e., have a Z score near 0) are excluded. 
Inspection of the TSL plot reveals key features of PDGFR and EGFR substrates 
specificity. Similar to what was previously reported for RTKs, strong phosphorylation of 
peptides with fixed Glu or Asp residues at positions N-terminal to the tyrosine acceptor site 
were identified for EGFR and, to a lesser extent, for PDGFR.  In the case of PDGFR, our data 
also indicated profound selection for certain amino acids at multiple peptide positions, such 
as aromatic and positively charged amino acids. Selection for Met, Gly, and Val was also 
apparent in positions upstream of the phosphorylation site. Selection against positively 
charged amino acids was apparent at every position of EGFR, and especially in positions +1, 
+ 2, +3, +4 and +5 of PDGFR.  
To confirm the apparent substrate specificity between PDGFR and EGFR, I 
compared the phosphorylation of the following peptides: (Btn)-GGLPVPEYINQS-(NH2), 
(Btn)-GGAENAEYLRVA-(NH2), (Btn)-GGVDADEYLIPQ-(NH2), and (Btn)-
GGTDSNFYRALM-(NH2) (Figure 2.5). In agreement with the matrix analysis, I observed 
differential phosphorylation of the peptides by EGFR and PDGFR.  
In conclusion, our study suggests that our peptide screens could be employed to 
establish an optimal phosphorylation motif for RTKs and importantly, highlights 
differences among RTKs in their substrate preferences. 
 
2.6 RTKs with activity that leads to EMT and erlotinib resistance have similar 
substrate preferences 
Because we originally hypothesized that distinct substrate specificity underpins the 
diverse biological outputs observed among certain kinases, we next investigated whether c-
Met and EGFR T790M have distinct peptide phosphorylation specificities when compared 
to EGFR. In general. activation of EGFR results in increased proliferation of cells. However, 
activation of PDGFR, c-MET, and EGFR T790M results in modest proliferation but increased 
motility, acquisition of mesenchymal-like features and, in the context of cells harboring 
oncogenic EGFR mutations, increased erlotinib resistance (Rikova et al. 2007). 
Hence, I performed a positional scanning peptide library screen to generate a matrix 
for c-MET and EGFR-T790M (Figure 2.6). Interestingly, I observed partial similarity between 
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c-MET, EGFR-T790M, and PDGFR matrices. Similar to PDGFR, these RTKs can also 
phosphorylate peptides enriched in positively charged amino acids.  
 
2.7 Discussion 
Positional scanning utilizing an oriented peptide library enabled a systematic 
analysis of RTKs substrates preferences (Figure 2.4.A). One key concept emerging from such 
quantitative studies is the importance of disfavored residues in RTKs specificity. Distinct 
classes of selectively disfavored residues are evident in our studies. PDGFR disfavored 
aspartic acid residues in positions C-terminal to the phosphorylation site and glutamic acid 
residues in all positions and overall favored positively charged amino acids throughout the 
peptide. In contrast, EGFR disfavored positive charged amino acids at all position while it 
overall favored aspartic and glutamic acid. Aromatic residues were also negatively selected 
for in experiments with EGFR. 
Previous work suggested that all RTKs are acidophilic (Bose et al. 2006), however, 
our study indicates that this notion should be revisited. Although further detailed analysis 
is needed to allow a generalization of the observed differences between EGFR, PDGFR and 
c-MET to other kinases, our findings suggest that similar to Ser and Thr kinases also RTKs 
could in principle be subdivided into acidophilic and basophilic kinases.  
The difference in charged amino acids in preferred substrates strongly suggests 
structural differences in the RTK kinase domains to play an important role. Sequence 
comparison of PDGFR and EGFR kinase domains indicated these enzymes to be highly 
homologous and structurally similar, but also highlighted specific differences (Lemmon and 
Schlessinger 2010). Three-dimensional structures are available for EGFR and PDGFR as well 
as for c-MET and EGFR T790M. Hence a detailed comparison of the amino acids 
participating in substrate interaction in the catalytic pocket of RTKs can be informative in 
understanding RTK selectivity for acidic and basic residues present in the substrate. 
One corollary of our study is the potential contribution of substrate specificity in 
mediating biological differences among RTKs. In fact, we can envision that differences in 
phosphorylation of a particular substrate could change enzymatic activity, protein stability 
and/or interaction with other RTK effector molecules. The latter can be the case e.g. for SH2 
and PTB containing proteins.  
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Src homology 2 (SH2) and (PTB) domains are the largest family of interaction 
modules encoded by the human genome. By virtue of their ability to bind tyrosine-
phosphorylated polypeptides, SH2 domains are involved in very diverse signaling 
processes that regulate cell growth or differentiation, protein stability, gene transcription, 
and cytoskeletal rearrangements (Anderson et al. 1990; Matsuda et al. 1990; Moran et al. 
1990; Koch et al. 1991; Mayer et al. 1991; Seet et al. 2006). Although SH2 domains have been 
identified in some protozoa (King et al. 2003), but in parallel with tyrosine kinase evolution 
they have undergone a marked expansion in multi-cellular organisms. It is estimated that a 
cell harbors 120 non-redundant SH2 domains present in 110 unique proteins. Protein 
kinases and phosphatases, cytoskeletal proteins, regulators of small GTPases, and E3 
ubiquitin ligases among others contain SH2 domains. Not surprisingly, mutations in genes 
encoding some SH2 domain proteins are associated with human diseases (Liu et al. 2006). 
For example, missense mutations within the N-terminal SH2 domain of PTPN11/SHP2 are 
associated with the Noonan syndrome (Friedman et al. 1993), nonsense mutations in the 
SH2 domain of RASA1/RasGAP underlie basal cell carcinoma (Sayos et al. 1998), and a 
mutation or deletion of the SH2D1A SH2 domain causes the XLP syndrome (Tartaglia et al. 
2001). 
All characterized SH2 domains share the same structure of a central antiparallel 
Beta-sheet flanked by two alpha-helices (Booker et al. 1992; Eck et al. 1993). Despite these 
similarities, different SH2 domains recognize distinct peptide sequences. In general, 3–5 
residues C-terminal to the Tyr phosphorylated acceptor site govern the specificity of an SH2 
domain. Because a peptide usually lies perpendicular to the central beta-sheet of the bound 
SH2 domain in an extended conformation, the interaction between the SH2 domain and the 
peptide is largely independent of the context of the native protein from which the peptide is 
taken (Huang et al. 2008). 
Analysis of peptide preferences for all SH2 domains enabled the classification of 
human SH2 domains according to their specificity (Songyang et al. 1994b) and categorized 
SH2 domains into three groups. The first group of SH2 domains contain an aromatic residue 
such as Tyr or Phe at the +3 position; group two of SH2 domains harbor a hydrophobic 
residue such as Ile, Leu, Val, Cys, or Met at the same position; whereas group three, which 
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is composed solely of the STAT family of transcription regulators, has a hydrophilic residue 
such as Glu, Gln, or Lys.  
On the other hand, PTB domains are often found in scaffold proteins and usually 
contain additional domains and motifs that allow them to nucleate the formation of multi-
protein complexes (Kavanaugh and Williams 1994; Forman-Kay and Pawson 1999; Margolis 
et al. 1999; Yan et al. 2002). Based on structural comparisons, they have been grouped into 
three broad families, the insulin receptor substrate 1 [IRS-1]/Dok-like, Shc-like, and Dab-
like families (Uhlik et al. 2005). The minimal PTB domain fold consists of a central beta-
sandwich comprised of seven antiparallel beta-strands that is capped on one end by the C-
terminal alpha-helix and on the other by a variable length alpha-helix positioned between 
strands beta-1 and beta-2 (or beta-2 and beta-3) in the sequence (Smith et al. 2006). The 
canonical peptide-binding groove is located between the fifth beta-strand and the conserved 
C-terminal alpha-helix. Similar to SH2 domains, screening for PTB specificities revealed the 
importance of amino acids surrounding the Tyr phosphorylation site. Preferred binding 
motifs of PTB domains contain the NXXY consensus site. In the case of the PTB domain of 
Eps8 in particular it has been shown that in addition to the NXXY motif this PTB domain 
shows preference for hydrophobic amino acids at the -5 position and basic residues C-
terminal to tyrosine. The favored ligands typically contain arginine, lysine, or histidine at 
the +1 to +3 positions (Smith et al. 2006). This in principle implies that, as is the case to SH2 
domains, also different PTB domains can mediate distinct signaling downstream acidophilic 
or basophilic kinases. 
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Figure 2.1. Peptide library screen design. The top panel shows a schematic representation of the 198 peptide 
substrates that comprises the positional scanning peptide library. Shown are the degenerate peptides bearing an 
equimolar mixture of the 20 naturally occurring amino acids (X), the central fixed phosphotyrosine (Tyr), and a 
second fixed position bearing one of the twenty amino acids (Z).  The bottom panel depicts the degree of 
phosphorylation by a receptor tyrosine kinase of interest in the presence of (32p)ATP for two different peptides 
(phosphopeptide shown by filled circle, un-phosphopeptide shown by a white circle).  
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Figure 2.2. Peptide library design and kinase assay optimization. A) SDS-PAGE analysis of auto-phosphorylation of the 
tyrosine kinase domain and substrate (GST) phosphorylation by EGFR and PDGFR in the presence of radioactive (32p)ATP. 
Autoradiography (32P) on the left and Coomassie-stained (Coo-) on the right. Both EGFR and PDGFR at 10ng had 
comparable auto-phosphorylation. B) To establish the optimal concentration for both kinase and substrate an in vitro kinase 
assay was performed using  serial dilutions of EGFR with biotyniladed peptide Y992: (Btn)-GGVDADEYLIPQ-(NH2) also in 
decreasing concentrations. Kinase reaction was spotted onto a streptavidin membrane, washed, dried and analyzed by a 
phospho-imager. Gradient bars represent decreasing concentration of kinase (40 ng, 20 ng, 10ng, 5ng from left to right) and 
for peptide dilution concentrations (5 mM, 1 mM, 0.5 mM, 0.1 mM, top to bottom). C) Quantification of the dilution 
experiment to determine optimal concentration for the kinase assay.  
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Figure 2.3. Peptide library screen to compare the substrate specificity between EGFR wild type and PDGFR. 
Representative autoradiogram of the in vitro kinase assay performed for each kinase is shown. Respective kinases were 
incubated with complete degenerate peptide library utilizing determined concentrations (10ng for kinases and 0.5mM 
for peptides) at 37˚C for one hour in the presence of radioactive (32p)ATP.  The reactions were spotted onto a 
streptavidin membrane, washed, dried and analyzed by a phospho-imager. Amino acid order is shown above the 
library screen with initials and corresponding letter. Positions relative to the central fixed tyrosine are shown on the 
left of the library screen. 
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Figure 2.4. PSSM logo representation of results for EGFR and PDGFR as well as the identification of putative peptide substrates for 
PDGFR utilizing Scansite. Peptide library screens were performed for both kinases in triplicate, quantified and normalized to the 
phosphotyrosine in order to produce a scoring matrix logo for EGFR wild type(A) and PDGFR (B). The position-specific scoring 
matrices (PSSM) logo shown is a representative graph of the motif for each kinase and was created utilizing the Two Sample Logo 
(TSL) web-based application. TSL calculated and visualized the differences between two sets of aligned samples of amino acids with 
the z-score for three separate screens plotting 25% population of each screen with a p value of 0.05. Each stack of letters represents z-
scores for residues at a single substrate position; the height of the symbols will be proportional to the difference of relative frequencies 
of corresponding residues at a given position in the positive and negative sample, and the positions of the letters in the stack are sorted 
from bottom to top in ascending value by the z-score. Each residue code is colored to indicate its amino acid's physicochemical 
properties: blue, basic; red, acidic; black, hydrophobic and aromatic except Tyr (Y); and green, small and nucleophilic. C) The 
phosphorylation sites were ranked for PDGFR based on its optimal phosphorylation motif utilizing Scansite Motif Scanner. The PSSM 
logo was used to score protein databases to find candidate phosphorylation sequences of proteins with high-ranking motif matches. 
Ranking of phosphorylation sites represents a prediction from the PSSM that is subject to experimental validation. 
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Figure 2.5. Validation of EGFR and PDGFR preferential phosphorylation motifs.  The sequences of 
biotynilated peptides used to confirm differential phosphorylation are shown in the upper panel. Shown in 
the lower panel is the autoradiogram of an in vitro kinase assay. EGFR shown and PGFR (10ng) were 
incubated with serial dilutions of the peptides at 37˚C for one hour in the presence of radioactive (32p)ATP. 
The reactions were spotted onto a streptavidin membrane, washed, dried and analyzed by a phospho-
imager. Concentration of peptides varies from 5 mM to 1 mM, 0.5 mM, 0.1 mM. 
 63 
  
Figure 2.6. Peptide library screen to compare the substrate specificity between c-MET and EGFR-T790M. The degree of 
phosphorylation for each fixed amino acid position of the screen is shown for human [c-MET] and [EGFR-T790M] kinases. 
Representative autoradiogram of the in vitro kinase assay was performed using the same protocol previously described for EGFR 
and PDGFR. Kinases were incubated with a degenerate peptide library (10ng for kinases and 0.5mM for peptides) at 37˚C for one 
hour in the presence of radioactive (32p)ATP.  The reactions were spotted onto a streptavidin membrane, washed, dried and 
analyzed by a phospho-imager. Amino acid order is shown above the library screen with initials and corresponding letter. 
Positions relative to the central fixed tyrosine are shown on the left of the library screen. 
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Chapter 3: SOCS3 is differentially phosphorylated by PDGFR and 
EGFR 
 
3.1 Summary 
The results presented in Chapter 2 indicate profound differences in substrate 
specificity between EGFR and RTKs, such as PDGFR, whose activities lead to 
mesenchymalization of cells, increased motility, extra-cellular matrix invasion and, in 
certain contexts, erlotinib resistance. In principle, this suggests that peptide specificity could 
mediate the functional diversity observed among RTKs.  
To identify potential substrates differentially phosphorylated by RTKs underpinning 
PDGFR mediated EMT and erlotinib resistance, we performed a bioinformatics analysis. 
Among the potential candidates identified in silico, we found SOCS3.  
SOCS3 is part of one of the main negative feedback mechanisms regulating IL-6 
mediating signaling. Given the importance of IL-6 signaling in the control of EMT, and 
erlotinib resistance, we further validated SOCS3 as a preferential substrate.  
Biochemical evidence both in vitro and in vivo showed increased phosphorylation of 
SOCS3 by PDGFR, c-MET, and EGFR T790M when compared to EGFR.  
 
3.2 Highlights 
 Computational prediction identified SOCS3 as a potential differentially 
phosphorylated substrate SOCS3 is differentially phosphorylated by EGFR and 
PDGFR 
 MS analysis identified the SOCS3 Y165 residue as a preferential phosphorylation site 
for PDGFR 
 Mutagenesis studies confirmed the SOCS3 Y165 residue to be a preferential 
phosphorylation site for PDGFR 
 SOCS3 is also phosphorylated by other RTKs 
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RESULTS 
3.3 Computational prediction identified SOCS3 as a potential PDGFR- and EGFR- 
differentially phosphorylated substrate 
To identify potential substrates that are differentially phosphorylated by PDGFR and 
EFGR, we utilized a bio-informatic approach (Figure 2.4.B). Z scores computed as described 
in the previous chapter were used to search the SWISS-PROT database for human proteins 
containing optimal phosphorylation peptide motifs for PDGFR and EGFR.  The search was 
performed utilizing the option ‘Search Using Quick Matrix Method’ available through the 
Scansite website (Obenauer et al. 2003). This program allows users to define an approximate 
motif by specifying a short pattern of amino acids. Scansite makes a crude weight matrix 
based on inputs, assigning a score of 9.0 to residues in the primary preference row, a score 
of 4.5 to those in the secondary preference row and a score of 1.0 to all unspecified residues. 
The result of using the Quick Matrix Method is less quantitative than a normal database 
search, but in principle can yield useful results when only limited motif information is 
available. Using this method, we were able to obtain the list of proteins depicted in Figure 
2.4.C as potential substrates for PDGFR. Among these, we were particularly interested in 
SOCS3 as a putative PDGFR substrate. SOCS3, in fact, is part of one of the main negative 
feedback mechanisms regulating IL-6 mediating signaling. Given the importance of IL-6 
signaling in the control of EMT, and erlotinib resistance; SOCS3 phosphorylation could in 
principle explain the functional differences observed between EGFR and PDGFR. 
 
3.4 SOCS3 is differentially phosphorylated by EGFR and PDGFR 
Our in silico analysis identified residue Y165 of SOCS3 as a putative PDGFR 
substrate. To validate this hypothesis, we utilized biochemical approaches.  
As a first step, a recombinant SOCS3 protein was generated. I utilized an E.coli 
expression vector containing a glutathione S-transferase (GST) coding sequence linked to 
the open reading frame of SOCS3, as well as an empty GST-only control. This system allows 
for expression and purification of the recombinant protein under non-denaturing 
conditions. DNA sequencing was utilized to confirm the nature of the different constructs 
and exclude the presence of mutations. Glutathione purification yielded proteins that were 
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over 80% pure by Coomassie blue-stained SDS-PAGE gel. A Western blot analysis utilizing 
a SOCS3 specific antibody further confirmed the identity of the recombinant protein.  
To validate the phosphorylation of SOCS3 by PDGFR, I performed a kinase assay in 
which I incubated PDGFR or EGFR with either purified GST-SOCS3 or GST alone as control. 
The incubations were done in the presence of radioactive ATP following procedures 
described in the previous chapter. The phosphorylation was visualized via 
autoradiography, and the protein quantity was visualized by Coomassie-gel staining. After 
the kinase assay, the reactions were boiled and subjected to analysis by SDS-PAGE. 
Radioactive signals were detected using a Fujifilm FLA-5100 instrument (Fuji Medical 
Systems USA, Inc.), and band intensities were quantified using Multi-Gauge v2.3 software 
(FujiFilm). 
As shown in Figure 3.1B, the difference in SOCS3 phosphorylation between PDGFR 
and EGFR was dramatic. A Michaelis/Menten kinetic analysis was performed to confirm 
these differences. 100 ng of either EGFR or PDGFR was used to phosphorylate GST-SOCS3 
WT at concentrations that ranged from 2µg to 62.5ng. The reactions were performed as 
beforehand described (Figure 3.1C) and the image was analyzed using Prism 5 (GraphPad 
Software). As can be observed in Figure 3.1.D, the Km values ranged from a low 8 µM for 
PDGFR to a high 30µM for EGFR, indicating SOCS3 to be a preferential substrate for PDGFR 
compared to EGFR.  
 
3.5 MS analysis identify the SOCS3 Y165 residues as a preferential 
phosphorylation site for PDGFR compared to EGFR 
Having confirmed SOCS3 to be differentially phosphorylated by PDGFR compared 
to EGFR, we next sought to determine the identity of the tyrosine(s) differentially 
phosphorylated by PDGFR. SOCS3 in fact possesses multiple tyrosines that can potentially 
be phosphorylated by PDGFR (depicted by red numbers in Figure 3.2.B).  
When we analyzed the Z scores obtained by peptide scanning positional analysis, we 
identified the Y165 residue as the preferential substrate for PDGFR. To validate this 
observation, we utilized a MS based method. A kinase assay was performed as described 
above in which GST-SOCS3 was incubated in the presence of cold ATP with two different 
concentrations of PDGFR, EGFR, and no kinase as a negative control (Figure 3.3.A). The 
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reaction was then run in a denaturing SDS-PAGE gel and a band of the expected size (32 
kDa) was excised and digested in-gel with trypsin or GluC. Peptide pellets were diluted into 
25ul, and 10ul of the solution was injected into Orbitrap (LC/MS/MS) at the Stony Brook 
proteomics center (Figure 3.3.B). The mass spectrometer was set up to take the top three 
peptides and also constantly fragment masses of 679.33, 615.75, 671.78, as those are 
theoretical 2+ masses of phosphorylated peptides (SEYphosQLVVNAVR, 
TVNGHLDSYphosEK, AYYphosIYSGGEK). Peptide AYYIYSGGEK was found in similar 
numbers among the four samples but the phosphorylated version was detected only in the 
GST-SOCS3 sample with PDGFR (Figure 3.3.B). Interestingly, the second tyrosine in this 
peptide was detected by MS to be the residue phosphorylated by PDGFR, as previously 
predicted. In the case of EGFR, no significant phosphorylation on Y165 was observed.  
In summary, our data indicated that the Y165 residue constitutes a novel and unique 
PDGFR phosphorylation site.  
 
3.6 Mutagenesis studies confirmed SOCS3 Y165 residues to be a preferential 
phosphorylation site for PDGFR compared to EGFR 
To further confirm that the tyrosine phosphorylated by PDGFR was the Y165 
residue, we generated an N terminal FLAG SOCS3 recombinant protein in which the Y165 
residue was changed into phenylalanine by in vitro mutagenesis (Figure 3.4.A). As a positive 
control, I also generated the SOCS3 mutant Y204F, since SOCS3 was previously shown to be 
a phosphorylation site. We utilized the tTiGFP vector developed in the Lowe Laboratory 
that is a tetracycline-regulated mammalian expression system with a green fluorescent 
protein (GFP) marker of induction for expression. The expression of genes cloned into this 
vector is repressed in the absence of tetracycline and induced in the presence of tetracycline 
(Yao et al. 1998). In particular, we used a modified version of the well-characterized TRE-
CMV polymerase II promoter (TREtight) that is less leaky to drive tetracycline-inducible 
transcription of cDNAs in mammalian cells utilizing a retrovirus (Dickins et al2005; 
Stegmeier et al. 2005; Shin et al. 2006). The transcription is driven by the reverse tetracycline 
transactivator (rtTA), which is transfected in parallel and activated only in the presence of a 
tetracycline analog (Gossen et al. 1995). For induction of the Tet On system we utilized 
doxycycline which is similar to tetracycline in its mechanism of action, exhibits similar dose 
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response, and has been shown to have a longer half-life than tetracycline (48 hours vs. 24 
hours, respectively).  
The multiple cloning sites moiety of the vector was substituted with a DNA 
fragment containing two flag sequences N terminal to the ORF of SOCS3 wild type and of 
multiple SOCS3 mutants in which tyrosine residues were modified into phenylalanine. In 
addition we also cloned PDGFR complete open reading frame into TtIGFP vector. In all 
cases presence of mutations was excluded upon DNA sequencing and expression validated 
by western blot analysis.  
These constructs were the transiently co-transfected into HEK 293T cells under 
conditions that allow high expression levels in cells after 48h of transfection. Cells were then 
stimulated with PDGF-BB (10ng/µl) for two hours and cell extracts were immuno-
precipitated (IP) with a FLAG antibody. Levels of SOCS3 phosphorylation were 
subsequently assessed by western blot analysis using a phospho-tyrosine antibody. IP-
western results indicated that although there was a reduction in the phosphorylation, 
SOCS3 (165YFIY) could still be phosphorylated upon PDGFR stimulation (Figure 3.4.B).  
Since there are two other tyrosines flanking the Y165 residue, we reasoned that the 
introduction of the phenylalanine residue could have changed the substrate specificity of 
the other tyrosines rendering them better substrates. For that reason, we generated a 
construct in which all tyrosines present in proximity of the SOCS3 Y165 were mutated into 
phenylalanine (SOCS3 FFIF). The FFIF mutant SOCS3 expressed in cells (HEK 293T) could 
not be phosphorylated by PDGFR. Whereas the SOCS3 construct in which the Y204 residue 
previously shown to be phosphorylated by other RTK showed only minimal changes. 
 In conclusion, altogether these experiments confirmed that PDGFR can induce the 
phosphorylation of SOCS3 in vivo and that the Y165 and the surrounding tyrosines are 
likely the residue differentially phosphorylated by PDGFR compared to EGFR.  
 
3.7 In addition to PDGFR SOCS3 is phosphorylated by other RTKs 
We previously showed that other RTKs such as c-MET and EGFR T790M have 
similarly to EGFR increased preference for positively charged amino acids surrounding the 
tyrosine phosphorylation site. Hence, having showed that PDGFR phosphorylated SOCS3, I 
next sought to determine whether these kinases were also able to phosphorylate SOCS3. A 
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kinase assay was performed and revealed that both c-MET and EGFR T790M but not HER2 
were able to phosphorylate SOCS3 (Figure 3.5.A).  
To determine whether phosphorylation occurred at the same residues as for PDGFR, 
we then analyzed the spectrum of phosphorylation of different SOCS3 tyrosine containing-
peptides by MS (Figure 3.5.B). In this case the mass spectrometer was set to acquire 
constantly fragmented masses of 679.33, 615.75, and 671.78, which are the theoretical 2+ 
masses of phosphorylated peptides (SEYphosQLVVNAVR, TVNGHLDSYphosEK, 
AYYphosIYSGGEK) plus their respective unphosphorylated peptides. MS analysis 
confirmed that MET and EGFR-T790M were also able to phosphorylate SOCS3 at two 
positions: Y165 and Y167 (YY*IY*).  
As aforementioned all RTKs are derived from the evolution of an ancestral kinase. 
To determine whether phylogeny could explain substrates specificity, I tested the capability 
of other kinases belonging to different branches of the kinome tree to phosphorylate SOCS3.  
Because all kinases are able to auto-phosphorylate themselves, and because all these 
TKs harbor a similar number of tyrosine residues, to determine the concentration to use for 
each kinase in the kinase assay, we utilized auto-phosphorylation as an indirect 
measurement of their kinase activity. As shown in Figure 3.6.A, in addition to PDGFR, 
EGFR T790M and c-MET also IGFR, VEGFR, EPHA2, SRC, JAK, and TRKc were able to 
increase the phosphorylation of SOCS3. Hence, suggesting that substrate specificity has 
been acquired as separate trait during evolution (Figure 3.6.B). 
3.8 Discussion 
Our results provided evidence supporting SOCS3 as a preferential substrate for 
PDGFR. This conclusion is based on the observation that PDGFR phosphorylated SOCS3 in 
vitro and in vivo, while EGFR cannot. Although the proximity of multiple tyrosine residues 
impeded validation by mutagenesis of the tyrosine residue preferentially phosphorylated by 
PDGFR, altogether our data strongly suggested that SOCS3 Y165 or its surrounding 
tyrosines are required for PDGFR-mediated phosphorylation. One limitation of this study is 
the possibility that the introduction of Phe residues rather than Tyr could disrupt the 
conformation of SOCS3 in such a manner as to prevent the interaction with PDGFR. 
Although we cannot exclude this possibility, MS studies strongly support that Y165 was the 
only residue to be differentially phosphorylated by PDGFR. Of note, Y165 is also the residue 
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predicted to be most favorably phosphorylated by PDGFR based on our peptide screen 
experiment. 
Tyrosine residues when phosphorylated become good docking sites for 
phosphotyrosine binding (PTB) and SH2 domains (Pinna and Ruzzene 1996). Analysis of 
consensus binding sites for PTB and SH2 binding proteins revealed SOCS4 and SOCS5 to be 
the best candidates that could bind to Y165 of SOCS3. This is particularly exciting because it 
suggests that the phosphorylation of SOCS3 could in principle lead to the ubiquitination 
and degradation of SOCS3. 
It is common for SOCS proteins to induce the ubiquitination and degradation of 
other family members. For example, this has been previously observed for SOCS1 and 
SOCS3 (Rui et al. 2002). Similar to other SOCS family members, both SOCS4 and SOCS5 can 
induce ubiquitination upon binding to their substrates (Yoshimura et al. 2007).  
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Figure 3.1.  SOCS3 is differentially phosphorylated by PDGFR and EGFR. A) Schematic of IL-6mediated signaling. Upon IL-6 
stimulation, SOCS3 is transcribed. As part of a negative feedback mechanism, SOCS3 bind to JAK and the gp130 receptor at 
phosphotyrosine 759 (pY759) via its kinase inhibitory region (KIR) and Src homology 2 (SH2) domains, respectively, and inhibits 
JAK-STAT signaling. B) In vitro kinase assay with PDGFR and EGFR using 500ng of GST-SOCS3 and 100ng of kinase in the 
presence of radioactive (32p)ATP is shown as an autoradiography (32P) on the right and as a Coomassie-stained SDS-PAGE gel 
(Coo-) on the left. Differently from EGFR, PDGFR highly phosphorylates SOCS3. C) An in vitro kinase assay was performed using 
same concentration for both kinases PDGFR (on left) and EGFR (on right) with decreasing concentration of GST-SOCS3 substrate 
shown as an autoradiography (32P).  Kinase reaction was ran in an SDS-PAGE gel, washed and analyzed by a phospho-imager. 
Gradient bars represent decreasing concentration of substrate (2µg, 1 µg, 500ng, 250ng, 125ng, 62.5ng). D) Michaelis-Menten 
analysis of SOCS3 phosphorylation by both PDGFR (pink) and EGFR (dark blue) using Prism 5 (GraphPad Software).  
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Figure 3.2. SOCS3 structure. A) Crystal Structure of SOCS3 in complex with the gp130(pTyr757) phosphopeptide shown in 
ribbon diagram of SOCS3 (green) with the bound gp130 phosphopeptide (purple) (modified from Bergamin, et al 2006). 
Potential tyrosine residues in SOCS3 phosphorylated by PDGFR are indicated in yellow. This figure was rendered with 
MacPyMOL. B) Schematic representation of SOCS3 showing the regulatory domains and all potential tyrosine residues (Y) 
that can be phosphorylated by PDGFR. The numbers in red index the scores predicted by comparison of substrate affinity to 
PSSM logo as shown in table.  
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Figure 3.3. SOCS3 phosphorylation by PDGFR and EGFR by MS. A) In vitro kinase assay using 500ng of GST-SOCS3 with 
PDGFR (100ng), PDGFR (5ng), EGFR (100ng) and no kinase as a control (MOCK experiment) were performed  in the presence 
of cold ATP. The reaction was run in a denaturing SDS-PAGE gel and stained with EZ blue to assess whether equal amount 
of recombinant SOCS3 was used. The bands were cut and analyzed by MS analysis. B) MS analysis revealed SOCS3 Y165 to 
be the preferential PDGFR phosphorylation site. The band of the expected size (32 kDa) was excised from the SDS-PAGE gel 
above and digested in-gel with trypsin or GluC. Shown is the unphosphorylated peptide (grey background with black peaks) 
and phosphorylated peptide MS analysis (white background with red peaks) for SOCS3 Y165. Peptide AYYIYSGGEK was 
found in similar numbers among the four samples; however, the phosphorylated version was detected only in GST-SOCS3 
sample with PDGFR (**). 
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Figure 3.4.  Validation of Y165 as a novel SOCS3 site of phosphorylation by PDGFR. A) Diagram of SOCS3 constructs 
utilized in the study. All constructs were tagged with FLAG peptide (red box) N terminal to the SOCS3 open reading 
frame and cloned into the tTiGFP vector (white box). All three tyrosine found by MS analysis to be preferentially 
phosphorylated by PDGFR are depicted (Y). Mutated residues for each SOCS3 construct is shown in red with the 
appropriate amino acid substitution (Y-F and Y-D). B) Hek293T cells were transiently co-transfected with tTiGFP-
PDGFRa in combination with Flag tagged SOCS3-WT, SOCS3-YFIF, SOCS3-FFIF, SOCS3-Y204F and their respective 
controls: empty vector (tTiGFP), tTiGFP-SOCS3 alone and tTiGFP-PDGFRa alone. 90% GFP expression was observed 
at the time of collection. Samples were immuno-precipitated with anti-Flag beads and western-blotted for 
phosphorylation using specific phospho-tyrosine antibody. The total protein levels of SOCS3 and PDGFR-alpha 
protein were visualized using anti-PDGFR-alpha and Flag antibodies. Loading control was visualized using a Tubulin 
antibody. 
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Figure 3.5. Differential phosphorylation of SOCS3 by RTKs. A) In vitro kinase assay was performed using 500ng of GST-SOCS3 or 
GST alone in the presence of EGFR T790M, EGFR, MET, Her2, PDGFR active kinases (100ng) and of radioactive (32p)ATP. The 
result is shown as an autoradiography (32P). B) MS was used to identify the tyrosine residues phosphorylated by c-MET and 
EGFR T790M. Similarly to what described beforehand, a kinase assay was performed in the presence of cold ATP. The kinase 
assay was run in a denaturing SDS-PAGE gel, stained with EZ blue and sent for further MS analysis at Stony Brook Proteomics 
Center. The elution profiles are shown for the unphosphorylated peptide (unphos) and phosphorylated peptide (phos) for SOCS3 
Y165 are shown. Peptide AYYIYSGGEK was found to be phosphorylated among the four samples; however, the MS analysis 
detected two tyrosine phosphorylation sites in the SOCS3 Y165 peptide for both EGFR-T790M and MET depicted in red numbers 
(1 and 2). Only one GST-SOCS3 phosphorylation site was detected with PDGFR. 
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Figure 3.6. Kinome phosphorylation profile of SOCS3. A) In vitro kinase assay was performed using 500ng of GST-SOCS3 with 
EGFR, PDGFR, cMET, IGFR, VGFR, FGFR, Epha2, SRC, JAK, DDR2, TRKc, AXL active kinases (100ng) and no kinase as control in 
the presence of radioactive (32p)ATP shown as an autoradiography (32P) and Coomassie-stained SDS-PAGE(Coo-). The 
arrowhead indicates the position of GST-SOCS3 and the kinases autophosphorylation. B) Cartoon of the phylogenetic tree of 
tyrosine kinases is shown.  Kinases that can phosphorylate SOCS3 are highlighted by yellow boxes,  the one that are unable to 
phosphorylate SOCS3 are in black boxes.  
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Chapter 4: PDGFR induced migration and erlotinib resistance is 
mediated by a sustained IL-6 through the phosphorylation dependent 
degradation of SOCS3 
 
4.1 Summary 
Cytokines regulate a variety of aspects of cell growth and differentiation. In 
particular, Interleukin (IL-6) has been shown to play a critical role in inflammation, tissue 
regeneration and tumorigenesis. Here we showed that SOCS3 is a critical node in 
coordinating the interaction of PDGF and IL-6 signaling. PDGFR can in fact directly 
phosphorylate SOCS3 and induce its rapid degradation via ubiquitination and proteasomal 
degradation. As a result when cells are stimulated with IL-6, SOCS3 fails to block IL-6 
signaling. Phenotypically this seems to be correlated with EMT, increased metastatic spread 
and erlotinib resistance.  
Because the biological activity of IL-6 seems to be context dependent, our findings 
provided further support to the notion that biological output is the result of integration 
among interconnected and intricate networks. In principle, these observations can provide a 
molecular framework for the contingency of cellular signaling and substrate specificity. 
 
 
4.2 Highlights 
 SOCS3 Y165 phosphorylation induces SOCS3 ubiquitination and degradation 
 PDGFR-mediated phosphorylation results in sustained IL-6 signaling 
 PDGFR-mediated phosphorylation of SOCS3 cooperates with IL-6 signaling in 
inducing EMT and erlotinib resistance 
 
4.3 Introduction 
Cytokines regulate a variety of aspects of cell growth and differentiation through 
their interactions with cytokine-specific receptors. These biological effect are mediated 
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through the activation of Janus kinases (JAKs) and activators of transcription (STATs) as 
shown in Figure 3.1.A (Ihle 1996; Darnell 1997). The activities of the JAK/STAT pathways 
are tightly regulated by the suppressor of cytokine signaling (SOCS) proteins. This family of 
proteins is characterized by the presence of an SH2 domain and a conserved motif termed 
the SOCS box (Starr and Hilton 1998; Yoshimura 1998). SOCS proteins suppress cytokine 
signaling through interactions between their SH2 domains and tyrosine phosphorylation 
sites on cytokine receptors or on JAKs. The SOCS activities include competing for the 
recruitment of other signaling proteins, directly blocking the catalytic activity of the kinases 
and/or targeting the proteins for degradation through recruitment of ubiquitination 
complexes through their SOCS box domain. For instance, SOCS proteins have been shown 
to form an E3-ubiquitin ligase complex with elonginC, elonginB, cullin2/5, and ring box 
protein-1 (Kamura et al. 2001). Several studies reported that the C-terminal SOCS box of 
SOCS1 and SOCS3, which interacts with elonginC, is required for proteasomal degradation 
of SOCS binding partners, such as TEL-JAK2, JAK2, Vav, and insulin receptor substrate-1 
and -2 (De Sepulveda et al. 2000; Frantsve et al. 2001; Kamizono et al. 2001; Rui et al. 2002; 
Ungureanu et al. 2002).  
The physiological functions of the SOCS family members have been investigated 
through experiments using knockout mice. For instance, SOCS1 deficiency results in a 
perinatal lethality that is associated with altered T-cell development and interferon 
signaling (Alexander et al. 1999; Marine et al. 1999b). SOCS2 deficiency results in a 
phenotype consistent with a primary role in growth hormone signaling (Metcalf et al. 2000). 
SOCS6-deficient mice are normal, with the exception that they weigh 10% less than wild-
type littermates (Krebs et al. 2002). In the case of SOCS3, disruption of the gene results 
instead in embryonic lethality, although the timing of the lethality varies depending on the 
study. In one study, embryos were obtained beyond mid-gestation and frequently were 
found to exhibit an erythrocytosis phenotype (Marine et al. 1999a). In a subsequent study, 
no embryos were found beyond mid-gestation, and analysis of erythropoiesis at this stage 
failed to identify any phenotypic alterations (Roberts et al. 2001). However, there were 
detectable phenotypic alterations in placental morphology, suggesting a role for SOCS3 in 
placental development. Tetraploid complementation rescued the placenta defects, yet 
SOCS3 mice died prenatally likely due to major cardiac defects (Roberts et al. 2001). 
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In contrast to the other SOCS genes, SOCS3 is induced by a broad spectrum of 
cytokines including IL-6, leptin, ciliary neurotrophic factor (CNTF) and leukemia inhibitory 
factor (LIF), as well as by factors such as lipopolysaccharide (Starr et al. 1997; Bjørbæk et al. 
1998; Bjørbæk et al. 1999; Ito et al. 1999; Stoiber et al. 1999). As with the other SOCS proteins, 
over-expression of SOCS3 can suppress responses to a number of cytokines. Thus far, 
SOCS3 has been proven to be an inhibitor of signal transduction for LIF, IL-11, IL-6, GH, 
insulin, EGF and leptin (Bjørbæk et al. 1998; Bjørbæk et al. 1999; Hansen et al. 1999; 
Nicholson et al. 1999; Sasaki et al. 1999).  
Of particular interest to us is the regulation of the IL-6 pathway. IL-6 is a pleiotropic 
cytokine secreted by a number of different cell types that exert both paracrine and autocrine 
stimulation. Increased production of IL-6 was  implicated in various disease processes, such 
as Alzheimer’s disease, autoimmunity (e.g., rheumatoid arthritis), inflammation, myocardial 
infarction, Paget’s disease, and osteoporosis, as well as in tumorigenesis (Kishimoto et al. 
1995; Jones et al. 2001). Examples of tumorigenesis include breast cancer, colon cancer, 
hepatocellular carcinoma, cholangiocarcinoma, glioblastoma, pancreatic cancer, NSCLC, 
prostatic and bladder cancers, and B-cell malignancies (Castleman’s disease) (Kishimoto 
2010). In particular our lab and others showed that stimulation of cells with IL-6 can lead to 
increased resistance to chemotherapy and in certain context to EMT (Yao et al. 2010). 
IL-6 binds to a heterodimeric receptor composed of an IL-6R (IL-6R, or CD126) and 
two molecules of gp130  (CD130)(Kishimoto et al. 1992; Ward et al. 1994). Wjile CD126 is 
highly specific for IL-6, gp130 is a common signal-transducing receptor for a subfamily of 
cytokines (the gp130 cytokine family) which includes IL-6, IL-11, LIF, ciliary neurotrophic 
factor, oncostatin M, cardiotropin-1, and neurotrophin-1 (Kishimoto et al. 1992).  
Upon activation, gp130 was shown to bind to JAK1, JAK2, and TYK2 (Lutticken et al. 
1994; Hermanns et al. 1999; Radtke et al. 2002). Of these interactions, the one with JAK1 
plays an essential role, because in cells lacking JAK1, IL-6-mediated transduction is greatly 
impaired (Guschin et al. 1995; Rodig et al. 1998). Activation of the Janus kinases upon IL-6 
stimulation induces IL-6-receptor phosphorylation and subsequent recruitment of signaling 
proteins. Among these is STAT3, which binds to the four tyrosine residues of gp130 (Tyr-
767, Tyr-814, Tyr-905, and Tyr-915), becomes phosphorylated in a JAK dependent manner, 
 82 
and translocates to the nucleus to induce IL-6-responsive genes (Wegenka et al. 1993; Stahl 
et al. 1995; Gerhartz et al. 1996; Schmitz et al. 2000).  
Tyrosine 759 of gp130 was suggested to be involved in the inhibition of IL-6 
signaling, since mutation of this tyrosine to phenylalanine enhances IL-6 signaling (Kim et 
al. 1998; Schaper et al. 1998). It was demonstrated that Tyr-759 can recruit both the tyrosine 
phosphatase SHP-2 and SOCS3. SHP-2 was shown to negatively regulate the IL-6 signaling 
pathway, but it was also reported that recruitment of SHP-2 to gp130 functions as an 
adaptor and leads to Ras/mitogen-activated protein kinase activation (Fukada et al. 1996; 
Lehmann et al. 2003) (Figure 3.2.A).  
Consistent with the importance of SOCS3 in regulating critical signaling pathways, 
SOCS3 has been recently shown to play a critical role in cardiac development, in 
neuroregeneration, in fibrosis, and in the onset and progression of tumors (e.g., 
colangyocarcinoma, pancreatic cancer, hepatocellular carcinoma) (Yoshimura et al 2007). 
Decreasing the expression of SOCS3 in tumor-derived cell lines also resulted in epithelial to 
mesenchymal transition and in increased pro-metastatic features. Although the mechanism 
of SOCS-3 induced metastasis is not fully understood it seems that it might be linked to 
increased activation of the IL-6 pathway and to hyper-activation of PYK2 (Zhang et al. 
2008).  
Decreased expression of SOCS3 has been observed in tumors and correlated to 
increased metastatic spread. Studies have reported increased promoter methylation in 
SOCS3 in certain tumors (Nakagawa et al. 2008). In addition, SOCS3 functions have been 
shown to be regulated by covalent modifications. For example, SOCS3 can be tyrosine-
phosphorylated upon stimulation with IL-2, IL-3, erythropoietin (Epo), epidermal growth 
factor, platelet-derived growth factor, and insulin (Cohney et al. 1999; Cacalano et al. 2001; 
Peraldi et al. 2001). This modification occurs on Tyr-204 and Tyr-221 within the SOCS box. It 
was reported that phosphorylated of Tyr-204 and Tyr-221 of SOCS3 works as a docking site 
for p120RasGAP and results in a sustained extracellular signal-regulated kinase activation 
(Cacalano et al. 2001; Haan et al. 2003).  
Based on these lines of evidence, we hypothesized that the phosphorylation of 
SOCS3 by PDGFR could represent an important node of integration of signaling mediated 
by these extra-cellular cues. Given the relevance of both PDGFR and IL-6, understanding the 
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impact of SOCS3 phosphorylation could provide, in principle, useful insights into the 
development of therapies for the treatment of many diseases such as inflammatory diseases 
and cancer, in which, hyper-cytokine signaling is usually involved.  
We found that Y165 phosphorylation resulted in increased ubiquitination of SOCS3 
and its proteasomal-mediated degradation. This in turns leads to a sustained activation of 
signaling pathways downstream of IL-6 stimulation. Preliminary data suggest that as a 
result of this sustained signaling activity, the cells undergo EMT and acquire increased 
metastatic potential as well as increased erlotinib resistance. 
 
 
RESULTS 
4.4 SOCS3 Y165 phosphorylation induces SOCS3 ubiquitination and degradation 
Having revealed SOCS3 to be a PDGFR substrate, we next conducted studies aimed 
at better understanding the biological significance of the phosphorylation at the identified 
residue. To this end, I cloned the wild type SOCS3, as well as two variants, in which residue 
Y165 (and the surrounding residues Y164, Y167) were mutated into a phenylalanine or an 
aspartic acid using the Tet-ON system described above. We termed these constructs SOCS3 
FFIF (Y to F) and SOCS3 DDID (Y to D). Of note, whereas the SOCS3 FFIF protein cannot be 
phosphorylated by PDGFR and thereby it simulates a constitutive un-phosphorylated form; 
the SOCS3 DDID mimics a constitutively phosphorylated form of SOCS3. After the 
retroviral constructs (tTiGFP) were established and sequence verified, I was able to 
successfully express SOCS3 WT and mutants in the NSCLC cell line H1650 and generate 
stable cell lines (Figure 4.1.A). This particular cell line was derived from the pleural effusion 
of a 27 years old male patient affected by NSCLC, harbors an oncogenic mutation of EGFR 
and is sensitive to erlotinib, an EGFR-selective inhibitor used in the clinic for the treatment 
of certain NSCLC (Lynch et al. 2004). Using the Tet-ON system, strong expression of the 
SOCS3 transcript was achieved after 48h of doxycycline induction. To enrich for infected 
cells, GFP-positive cells were retrieved from a heterogeneous population by flow cytometry 
assisted cell sorting (FACS) (Figure 4.1.B).  
Interestingly, when I analyzed expression of the different SOCS3 constructs by 
Western-blot analysis after doxycycline induction of the different SOCS3 constructs in 
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H1650 cells, I observed that the SOCS3 DDID construct was consistently expressed at lower 
levels than SOCS3 wild type and the SOCS3 FFIF mutant (Figure 4.1.C).  
To rule out that this decrease in protein levels was due to differences in the levels of 
transcription for the different constructs, I analyzed mRNA levels of SOCS3. I utilized 
primers spanning the vector boundaries to selectively amplify the ectopically expressed 
SOCS3 transcript. RT-QPCR analysis indicated similar mRNA level of expression for all 
constructs, suggesting a post-transcriptional mechanism of regulation may be responsible 
for the decrease of the constitutively phosphorylated form of SOCS3 (Figure 4.1.D).  
Although we did not directly measure the stability of SOCS3 and its variants, we 
hypothesized that SOCS3 phosphorylation could induce its ubiquitination and degradation. 
To determine whether ubiquitin-induced degradation was responsible for the observed 
differences, I immunoprecipitated the ectopically expressed SOCS3 constructs with an anti-
FLAG antibody and assessed the levels of ubiquitination by Western blot analysis using an 
ubiquitin-selective antibody. The results of the experiments, depicted in Figure 4.2.A, 
indeed show increased ubiquitination of the SOCS3 DDID construct compared to SOCS3 
WT and SOCS3 FFIF. 
Poly-ubiquitination is usually a signal for proteasomal degradation. To test the 
possibility that proteasomal degradation was responsible for decreased SOCS3 DDID levels, 
I inhibited the proteasome machinery in the SOCS3-overexpressing H1650 cells by treating 
cells with MG132, a potent and selective proteasome inhibitor (Figure 4.2.B). The levels of 
expression of the different SOCS3 constructs were measured by Western blot analysis. 
Treatment with MG132 was sufficient to increase SOCS3 DDID to levels that were 
comparable to the one observed in the case of SOCS3 wild-type construct. No major 
differences were observed for SOCS3 FFIF construct.  
In summary, we concluded that the phosphorylation of SOCS3 by PDGFR triggers 
rapid protein degradation by the proteasome machinery.  
 
4.5 PDGFR mediated phosphorylation results in sustained IL-6 signaling 
SOCS3 is one of main constituents of negative feedback mechanisms regulating IL-6 
signaling. Hence, we reasoned that PDGFR induces degradation of SOCS3 upon 
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phosphorylation, we could potentiate IL-6 mediated signaling by releasing its negative 
inhibition.  
To test this hypothesis, we first examined the status of activation of the IL-6 axis 
when the expression of SOCS3 was decreased using specific siRNA (Invitrogen). As an 
indirect measurement of IL-6 mediated signaling we evaluated the level of STAT3 and 
MAPK phosphorylation and its major down-stream signaling effectors upon stimulation of 
cells with IL-6 at different times. Consistent with published data, knock-down of SOCS3 
resulted  into a sustained STAT3 and MAPK phosphorylation upon IL-6 stimulation (Figure 
4.3.A).  
Next, we determined the effect of PDGFR stimulation on IL-6 mediated signaling. To 
this end, we utilized the stable NSCLC cell line over-expressing PDGFR described in 
Chapter 3, which was generated by the introduction of PDGFR under the control of a 
tetracycline-inducible promoter (tTiGFP). Treatment of cells with doxycycline for 48 hours 
induces a sustained expression of PDGFR (Figure 4.3.B).  However, dox-mediated PDGFR 
induction was not sufficient per se to activate the receptor.  Auto-phosphorylation of PDGFR 
in fact required stimulation by PDGF-BB (10ng/µl) as shown by the phosphotyrosine 
western-blot in Figure 4.3.B. When we analyzed the effect of activation of PDGFR on IL-6 
mediated signaling, we observed that expression of PDGFR alone did not change the levels 
of phosphorylation of STAT3, but stimulation with PDGF-BB and IL-6 appeared to cause a 
persistent STAT3 phosphorylation (Figure 4.3.B), similar to the case of cells in which SOCS3 
was silenced. 
To directly prove a causative role of SOCS3 phosphorylation in mediating the 
sustained IL-6 signaling, we then examined the activation of the IL-6 signaling in H1650 
cells ectopically expressing SOCS3 WT and SOCS3 mutations that mimic the 
phosphorylation and the unphosphorylated form of SOCS3 (SOCS3 FFIF and DDID), 
respectively.  
The expression of SOCS3 wild type or the constitutively phosphorylated form of 
SOCS3-DDID was induced with doxycycline for a period of 48h (Figure 4.4.A). SOCS3 
expression in cells in usually very low but it is induced 30 minutes after stimulation with IL-
6. Hence, to minimize the effects of endogenous SOCS3, we examined the effect of 
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ectopically expressed SOCS3 on IL-6 mediated signaling at early time points (e.g., 5, 10 ,15 
minutes). 
In cells expressing SOCS3 WT or the SOCS3 FFIF isoform, we observed a decrease in 
the levels of phosphorylation of STAT3 (Figure 4.4.A). The experiments were performed in 
triplicate and quantified using Odyssey® Software. As shown in the chart on the right side 
of Figure 4.4.A, while ectopically expression of SOCS3 was sufficient to reduce the 
phosphorylation of STAT3 upon stimulation with IL-6, expression of the SOCS3-DDID 
mutant failed to do so. This is consistent with the observation that SOCS-3 DDID is rapidly 
degraded in cells.  
To provide evidence that failure to decrease STAT3 phosphorylation was simply due 
to decreased protein expression and not due to other molecular mechanisms, we blocked the 
degradation of SOCS3 by treating the cells with a proteasome inhibitor (Figure 4.4.B), that 
we previously showed was sufficient to block SOCS3 degradation. Pre-treatment of cells 
with MG132 increased the levels of SOCS3-DDID and reduced the phosphorylation of 
STAT3 to a level comparable to the one observed in the SOCS3 wild type overexpressing 
cells. We interpreted this result as an indication that by decreasing the level of SOCS3, 
PDGFR could cooperate with IL-6 in activating STAT3-mediated signaling.  
 
4.6 PDGFR mediated phosphorylation of SOCS3 cooperates with IL-6 signaling in 
inducing EMT 
In the course of these experiments, it was noticed that PDGFR expressing cells 
acquired mesenchymal-like morphology when co-stimulated with IL-6 and PDGF-BB 
(Figure 4.5.A). This in principle suggests that the cooperation of PDGFR and IL-6 signaling 
pathways can be functionally important. Interestingly, the injection of H1650 cells 
overexpressing PDGFR resulted in lung metastasis when the mice were fed on doxycycline 
(Figure 4.5.B). 
To definitely test the importance of SOCS3 phosphorylation in the cooperation of IL-
6 and PDGFR, I constructed H1650 cells expressing inducible PDGFR and SOCS3 WT and 
SOCS3 FFIF mutant. If in fact the decreased expression of SOCS3 is required for mediating 
the effect of IL-6 stimulation, I should expect to see a failure of Il-6 in inducing 
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mesenchymalization of cells and in formation of metastasis. These experiments are 
underway. 
As IL-6 treatment can increase the cell resistance to erlotinib (Yao et al. 2010), I also 
determined whether treatment with PDGF-BB and IL-6 could modify the H1650-PDGFR 
cell’s sensitivity to erlotinib. As previously reported, treatment with IL-6 was sufficient to 
decrease the sensitivity of cells to erlotinib; however co-stimulation with PDGF-BB in H1650 
cells overexpressing PDGFR potentiated the IL-6 effect (Figure 4.5.C). Of note, PDGFR by 
itself had only minimal effect on erlotinib sensitivity. 
Our observations are of particular importance, as it has been argued that the 
activation of other RTKs including PDGFR in cells expressing oncogenic EGFR mutations 
lead to TKI resistance through compensatory mechanism via the activation of the PI3K 
pathway (Engelman et al. 2007). Our data, in principle, provide an alternative explanation 
and suggest resistance can be explained by a rearrangement of the signaling network 
downstream of RTKs. I am currently testing this hypothesis in cells expressing PDGFR as 
well as c-MET and EGFR T790M. 
 
4.7 Discussion 
Cytokines such as IL-6 have been shown to be important for inflammatory 
conditions, tissue regeneration and tumorigenesis. Yet, it has become evident that the effects 
of Il-6 are highly context dependent. For instance, while in certain cell lines, IL-6 can induce 
EMT and expansion of CD44+CD24- cells; in other cell lines, IL-6 stimulation fails to drive 
such phenotypes despite normal activation of IL-6 mediated signaling in cells. 
Here we showed that SOCS3 is a critical node in coordinating the interaction of 
PDGF and IL-6 signaling. PDGFR can in fact phosphorylate directly SOCS3 and induce its 
rapid degradation via ubiquitination and proteasomal mediated degradation. As a result 
when cells are stimulated with IL-6, SOCS3 fails to block Il-6 signaling. Phenotypically this 
seems to be correlated with EMT, increased metastatic spread and erlotinib resistance 
(Figure 4.6). 
These findings are of particular interest because PDGFR and IL-6 are co-activated in 
multiple biological systems. Thereby, our findings provided further support to the notion 
that biological output is the result of integration among interconnected and intricate 
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networks. In principle, these observations can provide a molecular framework for the 
contingency of cellular signaling and substrate specificity.  
In the context of tumorigenesis, our results can be particular relevant. PDGFR-, c-
MET- and EGFR T790M-over-expressing tumors are in fact characterized by an EMT 
phenotype, increased metastatic potential and erlotinib resistance. Our data argue that in 
these tumors, a sustained IL-6 signaling is mediating these phenotypes. We are currently 
exploring this hypothesis.   
It has been proposed that tumor phenotypes are driven not only by cell–autonomous 
mechanisms but also through the interaction with the microenvironment and with other 
tumor sub-populations. Interestingly, recent studies in glioblastoma have indicated that 
intra-tumor heterogeneity is important for the maintenance of distinct clonal populations 
(Szerlip et al. 2012). In particular, it has been shown that certain glioblastoma tumors 
harboring oncogenic EGFR mutations have elevated expression of IL-6. This in turn 
stimulates the proliferation of adjacent EGFR-expressing cells in a paracrine fashion (Inda et 
al. 2010). In addition, several groups have also described the existence in glioblastoma 
tumors of multiple clonal populations that harbor both EGFR and PDGFR over-expression 
(Szerlip et al. 2012). These observations, together with the fact that both Il-6 and PDGFR are 
secreted by activated components of the tumor microenvironment, suggest that the 
cooperation of IL-6 and PDGFR occur beyond a cell autonomous context. To this end, it 
would be interesting to determine whether phosphorylation or inactivation of SOCS3 plays 
a role in maintaining intra-tumor heterogeneity as well as in mediating certain effects of the 
tumor microenvironment on tumor onset and progression. In principle this can also be 
applied to tumors harboring c-MET amplifications and EGFR T790M mutations, as both of 
these receptors can phosphorylate SOCS3. Although, a more comprehensive analysis is 
required to make a strong inference, preliminary data indicate that NSCLC-derived cell 
lines harboring c-MET, PDGFR and T790M are characterized by a constitutive activation of 
the IL-6 pathway and low levels of SOCS3. Preliminary data also indicate that these cells are 
particularly sensitive to IL-6-pathway inhibition.  
Nonetheless, further studies are necessary to elucidate how sustained IL-6 activation 
can lead to EMT. Early data from our lab indicate that IL-6 hyper-activation can lead to EMT 
is not due to STAT3, as silencing of STAT3 is not sufficient to revert the EMT phenotype 
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observed in cells stimulated with IL-6. Similarly, we found that expression of a 
constitutively active STAT3 is not sufficient to induce EMT. Therefore, it can be reasoned 
that induction of EMT should be through other mechanisms upon SOCS3 phosphorylation. 
Since SOCS3 not only inhibits IL-6-mediated STAT3 activation, but it also negatively 
regulates many other signaling pathways. For instance, SOCS3 binds to the insulin receptor 
(IRS1/2) and induces their degradation (Elliott and Johnston 2004). Similarly, SOCS3 can 
also interact with EGFR and PYK2 to induce their ubiquitination and degradation 
(Yoshimura et al. 2007).   
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Figure 4.1. Functional analysis of SOCS3 phosphorylation in a NSCLC cell line. A) Diagram of Tet-ON inducible vector tTiGFP 
and rTtA used for mammalian expression of SOCS3 wild type and mutants. Note that rtTA expression from inducible transcript 
creates a positive feedback loop of TRE induction. B) Representative image at 5X magnification of NSCLC H1650 cells ectopically 
expressing SOCS3 under the control of the tetracycline-inducible promoter treated with doxycycline. SOCS3 wild type (WT), 
mutant SOCS3 FFIF (Y165-168F), mutant SOCS3 DDID (Y165-168D) were transfected into Ampho cells for retrovirus production, 
H1650 NSCLC were infected at a high MOI, selected and sorted for GFP expression after pulsing with doxycycline for 48h. C) 
Western Blot analysis indicated different protein levels of SOCS3. Total cell lysates were prepared and analyzed by Western Blot 
with a Flag antibody to detect tagged SOCS3-WT, SOCS3-FFIF, and SOCS3-DDID. The infection control is the empty vector 
(tTiGFP) and as a loading control RasGAP was used. D) Quantification of mRNA levels of the H1650 stable expressing SOCS3 
wild type and mutants by RT-QPCR analysis. H1650 stable expressing SOCS3 wild type and mutants were treated with 
doxycycline for 48h, RNA was isolated, and reverse transcriptase was used to amplify the cDNA for each sample and quantified 
by QPCR using Flag-SOCS3 primers. Each bar represents the mean of three experiments. Actin mRNA levels were used as 
reference. Error bars are standard deviation. 
A 
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Figure 4.2. Ubiquitination is responsible for the decrease expression of SOCS3-DDID isoform. A) To detect poly-
ubiquitination, H1650 cells with stable expression of SOCS3-WT, mutant SOCS3-FFIF, and mutant SOCS3-DDID or empty 
control vector were treated with doxycycline for 48H. Cell lysates were subjected to anti-FLAG immune-precipitation (IP), 
resolved by SDS-PAGE followed by immune-blotted with Ubiquitin antibody (Ub), FLAG antibody (Flag-SOCS3) and the IgG 
bands were used as a loading control. The arrowhead indicates the position of SOCS3 in the Ub immuno-blot. The chart below 
provides quantification of the western blot analysis. B) To determined whether the proteasome was responsible for the 
degradation of SOCS3-DDID in H1650 cells stably expressing SOCS3-WT, mutant SOCS3-FFIF, and mutant SOCS3-DDID or 
empty control vector, cells were treated with proteasome inhibitor MG132 (10 M) for four hours and collected as (A). 
Western Blot analysis indicated increased protein levels of SOCS3-DDID. Total cell lysates were prepared and analyzed by 
Western Blot with a Flag antibody to detect tagged SOCS3-WT, SOCS3-FFIF, and SOCS3-DDID. The infection control is the 
empty vector (tTiGFP) and as a loading control RasGAP was used.   
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Figure 4.3. Silencing of SOCS3 and PDGFR-alpha activation modifies IL-6 signaling pathway in NSCLC cells. A) H1650 cells 
were transfected with siRNA of SOCS3 (Invitrogen) and scramble siRNA control then treated with IL-6 (10ng/l) for the 
indicated times. Total cell lysates were prepared and analyzed by Western Blot with phosphoSTAT3 antibody (pSTAT3). The 
blots were reprobed with total STAT3 antibody for normalization. B) PDGFR-alpha cloned into the tTiGFP vector under the 
control of the tetracycline-inducible promoter and stably expressed in H1650 cells. H1650 cells with stable expression of 
PDGFR or empty control vector, were stimulated with PDGF-BB (10ng/l) ligand for two hours and pulsed for 10 minutes 
before collection as well as treated with IL-6 (10ng/l) for the indicated times. Total cell lysates were prepared and analyzed 
by Western Blots with phosphotyrosine antibody (P-Tyr) and phosphoSTAT3 antibody (pSTAT3). The blots were reprobed 
with total PDGFR-alpha antibody and total STAT3 antibody for normalization. Positive expression and activation of the Tet-
ON system was achieved. A representative Western Blot from three independent experiments is shown. 
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Figure 4.4. SOCS3 Y165 phosphorylation induced a sustained IL-6 signaling pathway. A) H1650 SOCS3 WT and mutant 
SOCS3 DDID or empty control vector were induced with doxycycline for 48h and treated with IL-6 (10ng/l) for the 
indicated times. Total cell lysates were prepared and analyzed by Western Blot with phosphoSTAT3 antibody 
(pSTAT3) and FLAG antibody (Flag-SOCS3). The blots were reprobed with total STAT3 antibody and Beta-tubulin for 
normalization. A representative Western Blot from three independent experiments is shown. Quantification of the 
Western Blot analysis using Odyssey to detect protein levels (Integrated Intensity) is shown on graph below. Error bars 
are standard deviation. B) H1650 SOCS3 WT and mutant SOCS3 DDID or empty control vector were induced and 
treated as (A) in the presence of the proteasome inhibitor MG132 (10 M) for four hours. Total cell lysates were 
prepared and analyzed as (A). A representative Western Blot from three independent experiments is shown. SOCS3-
DDID expression was increased and the level of phosphorylation of STAT3 was decreased.  
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Figure 4.5. PDGFR-alpha expression induces EMT, increased metastatic spread and erlotinib resistance in NSCLC 
derived cells. A) Representative image at 5X magnification of NSCLC H1650 cells overexpressing PDGFR-alpha under 
the control of the tetracycline-inducible promoter treated with doxycycline in the presence of IL-6 (10ng/l) and PDGF 
ligand (PDGF-BB) showed dramatic morphological differences. B) H1650-PDGFR-alpha cells or empty control vector 
were injected to immuno-compromised mice. After one month, mice were treated with doxycycline and tumor growth 
was monitored for a total of three months. When the tumor reached a volume of ∼100 mm3, mice were dissected. Sites 
of metastasis were observed in 2/3 H1650-PDGFR injected mice. Experiments were performed in triplicate for each cell 
line. C) The chart represents an erlotinib sensitivity assay performed on H1650-PDGFR-alpha cell line in the presence or 
absence of Il-6 and PDGF-BB. Drug sensitivity of cells was measured after 72 h of treatment by fixing with 
Formaldehyde and staining with Syto 60 (Invitrogen). The percentage of viable cells was calculated relative to 
untreated control. Sensitivity assays were performed in quadruple for each concentration shown on graph, error bars 
are standard deviation. 
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Figure 4.6. Proposed model of PDGFR phosphorylation of SOCS3 and its effects in modulating the IL-6 signaling 
cascade. PDGFR-alpha phosphorylates SOCS3 at residue Y165. Upon phosphorylation SOCS3 is poly-
ubiquitinated and degraded by the proteasome machinery. Decrease expression of SOCS3 increases the levels of 
Il-6 mediated signaling and leads to EMT, increased motility, invasion and drug resistance.  
 
 96 
 
 
SECTION III 
  
 97 
 
 
 
CHAPTER 5 
DISCUSSION AND FUTURE PERSPECTIVES 
 
  
 98 
Chapter 5: Discussion and Future perspectives 
 
Protein tyrosine kinases (PTKs) were first described in 1970s by Temin as viral 
transforming gene products. PTKs can be divided into two classes: the trans-membrane 
receptor tyrosine kinase (RTK) class and the non-receptor tyrosine kinase (NRTK) class, 
which are further grouped into subfamilies based on sequence similarity (Manning et al. 
2002). More than a quarter of a century ago, it was quickly recognized that RTKs in 
particular could play a role in transducing growth factor signals across the plasma 
membrane. Over time, it has become clear that RTKs control many different cellular 
functions by phosphorylating proteins involved in gene expression, metabolic pathways, 
cell growth and differentiation, membrane transport, and apoptosis (reviewed in Lemmon 
and Schlessinger 2010). In the early 1990s, several studies showed that viral transduction of 
the PDGFR ligand promoted cell transformation by activating this RTK through an 
autocrine loop (Doolittle et al. 1983; Waterfield et al. 1983). Subsequently, a gene encoding 
EGFR was shown to be amplified and mutated in brain tumors, causing the constitutive 
activation of downstream signaling in tumor tissues (Libermann et al. 1985). Over the past 
50 years, the importance of RTKs has been clearly demonstrated in multiple studies and 
increasing amounts of data have now implicated the deregulation of these signaling 
proteins in a variety of diseases.  
Aberrant activation of many RTKs due to amplification, activating mutations, or 
ligand over-expression has been observed in multiple tumor types (Gschewind 2004). In 
lung cancer in particular, over-expression of EGFR, HER2, FGFR, PDGFR, or c-MET occur at 
a high frequency together with certain oncogenic EGFR mutations. Altogether, the genetic 
lesions observed in RTKs account for the vast majority of known oncogenic lesions observed 
in this disease (Ding et al. 2008).  
At the functional level, deregulation of RTKs activity is important in mediating 
multiple aspects of tumorigenesis. Increased activation of RTKs has been shown to increase 
cell proliferation, metastasis, DNA damage, protection from apoptosis and to modify the 
micro-environment and cell metabolism (Fukada et al. 1996; Lehmann et al. 2003).  
Although highly similar in their structure and regulation, different RTKs exert 
distinct biological functions. The ability of RTKs to signal through common pathways while 
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inducing diverse phenotypic responses has largely been attributed to differences in cellular 
context (Jordan et al. 2000; Simon 2000). For example, while FGFR1 induces differentiation 
in neuronal cells, in fibroblasts it increases proliferation (Marshall 1995; Lin et al. 1996). 
When expressed in the same cellular background however, different RTKs have also been 
shown to elicit different phenotypic responses. For instance, activation of EGFR induces 
proliferation in PC12 neuronal cells, whereas activation of FGFR1 induces differentiation 
(Pollock et al. 1990; Lin et al. 1996). Recently, Miller-Jensen et al (2007) showed that the 
phenotypic response of cells to external stimuli can be predicted using models that rely on 
linear combinations of a common set of downstream signaling proteins. This suggests that 
different RTKs may be able to elicit different phenotypic responses in the same cell type by 
activating a common set of signaling proteins, but to different quantitative degrees. In this 
model, the integration of signaling elicited by RTKs at multiple levels determines the 
cellular outcome.  
In my study, I showed that in addition to these mechanisms, intrinsic differences in 
RTK substrate specificities could also play a role in modulating functional outcomes. In 
particular, the work in this thesis presents evidence indicating that certain RTKs, such as 
PDGFR and MET, have site-specific phosphorylation preferences for particular peptides. For 
instance, PDGFR showed increased selectivity for positively charged peptides. Hence, 
similar to the case of serine and threonine kinases, our data suggests that RTKs could also be 
sub-divided into acidophilic and basophilic kinases. Further experiments analyzing a broad 
number of RTKs will be required to validate this notion. Nonetheless, the difference in 
charge of preferred peptides strongly implies that these variations are due to structural 
divergence in the kinase domain. In this regard, the observation that a single amino acid 
change in mutant EGFR (T790M) is sufficient to modify substrate specificity is of particular 
interest. Crystal structures of multiple kinase domains are now available in complexes with 
pseudo-substrates. We are currently conducting studies in collaboration with Hiroyasu 
Furukawa (Hiro) at CSHL aimed at identifying possible structural variations among RTKs 
that could support our findings.  
To identify possible PDGFR selective substrates, we conducted a bioinformatics 
analysis and identified SOCS3 as a potential candidate that is differentially phosphorylated 
by PDGFR and EGFR. In vitro and in vivo studies confirmed these predictions through MS, 
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mutagenesis, biochemical analysis and kinase assays. In particular, I found that upon 
phosphorylation of SOCS3, the protein is rapidly degraded. Given the preeminent role of 
SOCS3 as a component of the negative feedback loop of the IL-6 axis, our findings suggest 
that the decreased expression of SOCS3 upon PDGFR phosphorylation induces sustained 
IL-6 signaling. Indeed, PDGFR activation was important in prolonging the time of activation 
of STAT3 upon IL-6 stimulation. Functionally this overexpression resulted in an increase of 
EMT, motility, and erlotinib resistance.  
These results are intriguing, because they reinforce the notion that the biological 
output of signaling pathways is highly context-dependent. For instance, the simple 
stimulation with PDGF-BB in cells expressing PDGFR was not sufficient to induce the above 
phenotypes; however, when the cells were co-stimulated with PDGF-BB and IL-6, they 
acquired a mesenchymal phenotype.  
The fact that SOCS3 is regulated at the protein level by PDGFR is also exciting 
because it allows for faster regulation of signaling cascades compared to regulation at the 
transcriptional level. Yet, because the numbers of players (SOCS3 phosphorylation and 
ubiquitination) is restricted in this case, this mode of signaling integration can increase 
plasticity at the expense of robustness.  
As mentioned previously, SH2 and PTB domains are the largest family of interaction 
modules encoded by the human genome which recognize tyrosine-phosphorylated 
sequences. Therefore, these domains play pivotal roles in transducing and controlling 
cellular signals from PTKs. By virtue of their ability to bind tyrosine-phosphorylated 
polypeptides (Schlessinger and Lemmon 2003), the domains are involved in signaling 
processes that regulate cell growth or differentiation, protein ubiquitination and/or 
degradation, gene transcription, and cytoskeletal rearrangements (Pawson 2004; Kirkin and 
Dikic 2007). Thus, differences in amino acid preferences for substrate recognition could have 
an impact on the class of PTB and SH2 domain proteins with which PDGFR substrates can 
interact. This may be the case in these studies, which showed that SOCS3 was ubiquitinated 
and degraded in response to phosphorylation at position Y165, which is a potential binding 
site for the SH2 domain of SOCS4 and SOCS5. 
IL-6-, PDGFR-, and c-MET-mediated signaling are not only relevant for NSCLC, but 
have been shown to be important in many other tumor types. It would be interesting to 
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explore the relevance of integration of RTKs and IL-6-mediated signaling in other contexts, 
such as HCC, glioblastoma, and pancreatic cancers. In these tumors, clear roles for IL-6, 
PDGFR, and c-MET have been elucidated in both cell culture systems and animal models.  
In the case of glioblastoma, IL-6 paracrine stimulation has been shown to be important in 
driving tumorigenesis. Interestingly, a recent publication also indicated the existence of 
heterogeneous distribution of PDGFR and EGFR in certain glioblastoma tumors. This 
observation suggests the possibility that IL-6 and PDGFR could cooperate in increasing the 
expression of IL-6 and other secreted factors, and in doing so contribute to the proliferation 
of neighboring clonal populations (Szerlip et al. 2012). Since IL-6 receptor, PDGFR, and c-
MET are not only expressed in tumor cells but also in other components of the tumor micro-
environment, this model could explain cooperation between tumor-associated fibroblasts, 
macrophages, platelets, and the tumor cells themselves during tumorigenesis.  
Besides tumorigenesis, the importance of other physio-pathological conditions in 
which PDGFR and IL-6 have been shown to play a role cannot be excluded.  These 
conditions include rheumatoid arthritis, fibrosis, and maintenance of stem cell self-renewal.  
While my study was exclusively focused on the IL-6 axis, SOCS3 regulates many 
other signaling pathways and it would be important to extend these studies to such systems. 
In fact, the deregulation of SOCS3 by PDGFR could have more profound effects than just the 
regulation of the IL-6 axis. For instance, SOCS3 has been shown to regulate IR, CTNF, 
interfon, and LIF. In the case of IR, decreased expression of SOCS3 has been shown to 
induce insulin resistance and in the case of CTNF, it increases neuronal regeneration 
(Yoshimura et al. 2007). The possibility that SOCS3 degradation could increase axonal 
growth after injury opens up potential therapeutic opportunities. For example, lowering 
SOCS3 expression either by localized delivery of siRNA oligonucleotides or by 
oligonucleotide-mediated premature SOCS3 poly-adenylation, it may be possible to increase 
axonal growth after neuronal damage or spinal cord injury. 
A final outcome of my thesis studies is the possibility of utilizing our novel findings 
of RTK substrate specificity to generate probes that could aid in the visualization of kinases 
in vivo. Fluorescence resonance energy transfer (FRET) has been used to confirm 
interactions between a kinase and a candidate substrate. Using information about known 
substrates, FRET-based reporters have been developed to measure the activity of specific 
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kinases in live cells (Zhang and Allen 2007). These reporters are single proteins that contain 
four major components: two forms of green fluorescent protein (CFP and YFP) at the N and 
C terminus, which form the FRET pair; a substrate domain for the kinase of interest; and, a 
phosphorylation binding domain, such as SH2 or 14-3-3 domains. In response to 
phosphorylation of the substrate domain of the reporter, the SH2 or 14-3-3 domain binds the 
substrate domain, thereby triggering a conformational change in the reporter that alters its 
FRET signal. Development of a Src reporter was recently described and used to study 
integrin signaling induced by local mechanical stimulation of endothelial cells (Wang et al. 
2005). Furthermore, a protein kinase A (PKA) FRET reporter has been adapted for high-
throughput drug screening to identify small-molecule kinase inhibitors and pathway-
modulating compounds. Therefore, I could use our observations to develop specific FRET 
substrate domains. Experiments such as this one open up a totally new direction for kinase 
and molecular target therapy innovation.  
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Appendix i: Phospho-proteomic analyses of signaling differences between 
PDGFR and EGFR in NSCLC 
Cells respond to external cues by transferring information from their surface to their 
inside.  To communicate information, phosphorylation of proteins has evolved as one of the 
most common modalities of signal transduction. (Ullrich and Schelessinger 1990). Protein 
phosphorylation is mediated by the protein kinase family, one of the largest enzyme super-
families in higher eukaryotes (Manning et al. 2002). Deregulation of kinase activity has been 
observed in multiple pathological conditions. In particular in the case of NSCLC, 
amplifications and mutations in members of a particular class of kinases, the receptor 
tyrosine kinases super-family, have been shown to be causing the disease. Thereby, a better 
understanding of the signaling network governed by RTKs can provide important insights 
into mechanisms controlling cell growth and oncogenic transformation.  
Mass Spectrometry (MS) is a sensitive and specific analytical tool that has been 
routinely and successfully applied to the identification and characterization of tyrosine 
phosphorylation-dependent signaling networks across biological systems. In collaboration 
with Dr. White’s laboratory I utilized MS-based studies to identify components of signaling 
pathways downstream EGFR and PDGFR. As described before, PDGFR and EGFR are 
aberrantly activated in NSCLC due to gene amplification, missense mutations or small in 
frame deletions.  
To compare changes in signaling downstream of oncogenic EGFR mutations and 
PDGFR in NSCLC, I utilized as a cell system based on H1650 cells ectopically expressing 
PDGFR in a doxycycline-inducible manner (See Chapter 4.5 for a detailed description of 
these cells). Of note, in cells subjected to doxycycline the PDGFR receptor is in an off-state 
unless PDGF ligand is added to the culture. To identify experimental conditions in which 
phosphorylation of target proteins was at its highest level, I tested different protocols in 
which I varied the time of serum starvation and stimulation of cells with EGF and PDGF-BB. 
Maximum phosphorylation levels were reached when I induced the expression of PDGFR 
for 2 days by treating cells with 1µg/ml of doxycycline, serum starved the cells for 16 hours 
and pulsed the cells twice with 10 ng of either PDGF-BB or EGF at 16 hours and again 15 
minutes prior to harvesting the cells. To further confirm the specificity of signaling I also 
treated cells with PDGFR and EGFR inhibitors as indicated in Figure A.1.2.  
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Treated cells were washed with pre-chilled PBS and lysed in 10 min intervals to 
allow time for proper collection. As a lysis protocol, I used a solution with 8M filtered urea, 
without detergents which is compatible with a subsequent protein precipitation for MS 
analysis. Cell lysates were divided into two aliquots and snap-frozen on dry ice for 
subsequent analysis. One aliquot was sent to Forest White’s laboratory for differential 
iTRAQ (isobaric tag for relative and absolute quantization) labeling, and the second aliquot 
was kept for western blot validation. Forrest White and colleagues recently used a similar 
protocol to generate temporal dynamic profiles of post-translational modifications from 
cells stimulated with EGF (Zhang et al. 2005), insulin (Schmelzle et al. 2006), and anti-CD3 
(Iwai et al. 2010). 
The iTRAQ method is based on the covalent labeling of the N-terminus and side 
chain amines of peptides from protein digestions with isobaric chemical labels that can be 
distinguished using MS (Figure A.1.1). There are currently two iTRAQ reagent sets (4-plex 
and 8-plex) that can be used to label all peptides from different samples. In my experiments, 
we used the 8-plex system.  
As part of the analysis that was done in Forest White’s laboratory, proteins were 
alkylated with 8 mM iodoacetamide, precipitated, and digested with trypsin and labeled 
with one of the isobaric reagent sets. Samples were next combined and subjected to a two-
dimensional LC-MS workflow.  Peptides remain isobaric in MS, but following collision-
induced dissociation (CID) with the iTRAQ reporter ions appear as distinct ions in the range 
113 to 121 Da. The relative expression levels of the peptides (and thus corresponding 
proteins) were deduced directly from relative intensities of the corresponding reporter ions.  
Using the Orbitrap Velos MS, acquisition parameters were set to acquire consecutive 
CID and high-energy collision spectra (HCD) for identification and iTRAQ quantification n, 
with the top 4-6 most intense ions selected. Peak lists were extracted from instrument raw 
data files using the MASCOT Distiller software (MatrixScience). iTRAQ quantitation was 
handled by MASCOT, MASCOT Integra or SCAFFOLD Q+ software (Perkins et al. 1999). 
Only proteins with a score of p > 0.05 (greater than 95% confidence interval) were accepted 
for positive identification. In addition, accepted protein identifications required a "Local 
False Discovery Rate (FDR)" estimation of no higher than 2%, as calculated by the Mascot 
Percolator algorithm. 
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Phosphorylation occurs most often on serine (accounting for ∼90%), and threonine 
(accounting for ∼10%) residues, with tyrosine phosphorylation accounting for only ∼0.05% 
in eukaryotic cells (Hunter and Sefton 1980). Therefore, scoring these rare events requires 
enrichment techniques (Pandey et al. 2000). To focus the analysis on site-specific 
phosphorylation prior to LCMS analysis, enrichment strategies such as titanium dioxide, 
IMAC or immune-precipitation with phospho-specific antibodies can be utilized to remove 
non-phosphorylated peptides (Ruse et al. 2004; Sachon et al. 2006; Zhang et al. 2005). For my 
study we immunoprecipitated samples with a phospho-tyrosine specific antibody. 
The table in Figure A.1.2 shows the top hits of a differential phospho-proteomic 
analysis of PDGFR and EGFR activities. The iTRAQ values are shown as raw numbers 
rather than ratios, because there is no one channel that always has a detectable signal (ND 
means not detected – meaning the iTRAQ signal for this channel was too low for detection). 
However, although the signal and number of identified sites was relatively low, the trends 
in the data look promising, suggesting that expression of PDGFR increases phosphorylation 
of some sites, as does the treatment with the ligand. Additionally, the inhibitor treatments of 
the H1650 PDGFR NSCLC cells appear to be decreasing the phospho-peptide signaling. The 
data should be treated as just an indication of trends, as I have not validated the spectra for 
any of these sites.  
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Figure A.1.1. An overview of a proteomic procedure with iTRAQ reagents. Protein extracts from four 
different samples are trypsin digested. The resulting peptides are then labeled with isobaric tags and 
pooled for fractionation and analysis by MS/MS. Isobaric tag intensity corresponds to peptide abundance 
and is used for protein quantitation. Diagram obtained from White 2007. 
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Figure A.1.2. Characterization of RTKs signaling differences & similarities using phospho-proteomics. NSCLC 
H1650 cells overexpressing PDGFR were characterized in collaboration with Forest White’s Lab utilizing an 
iTRAQ 8-plex with phosphotyrosine enrichment. Low for detection iTRAQ values (ND). Interesting proteins 
with post-translation modifications are highlighted in green.  
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Appendix ii: Functional genomic screens to interrogate signaling differences 
among RTKs 
It has been observed that cells with EGFR oncogenic mutations when expressing 
PDGFR become more resistant to treatment with EGFR selective inhibitors that cells not 
expressing PDGFR. We reasoned that this could be accounted for by PDGFR-induced 
differences in the signaling network. This implies that cells expressing EGFR or PDGFR 
should be distinctly sensitive in the inactivation of signaling network components required 
for their proliferation or survival.  
In the late 1990’s and early 2000’s, the discovery of RNA interference (RNAi) 
provided a technology to perform genetic screen in mammalian cells (Fire et al. 1998; 
Brummelkamp et al. 2002; Paddison et al. 2004b; Silva et al. 2005). RNAi is a sequence-
specific, post-transcriptional gene-silencing process that is mediated by double-stranded 
RNA (dsRNA) molecules (reviewed in Moffat and Sabatini 2006). To identify EGFR and 
PDGFR regulated signaling constituents I utilized a functional genomic approach using 
RNAi technology developed by the laboratory of Dr. Hannon. In principle, this 
methodology allows for the identification of signaling components in the RTK pathways 
that are required for the survival and/or proliferation of cells. In contrast to the other 
strategies that I utilized in my studies, this approach might identify signaling components 
that are not directly regulated by RTK phosphorylation.  
During the past decade at CSHL Dr. Hannon’s laboratory has developed a blueprint 
that allows to effectively and functionally interrogate the human genome using RNAi-based 
strategies.  RNAi screens can be carried out using either siRNA-based transient transfection 
or shRNA-based stable gene knockdown. Vector-based shRNA libraries have several unique 
advantages that make them particularly attractive: targets can be screened in pools, thus 
significantly reducing the cost of the screen and they enable long-term gene knockdown 
thereby revealing phenotypic changes that may not materialize with short term strategies. 
A number of genome-wide shRNA libraries covering the human and mouse 
genomes have been constructed. They differ in size, coverage, shRNA sequence design, and, 
most importantly, strategies used to generate the miRNA-mimicking sequences for gene 
silencing.  As opposed to other libraries that utilize RNA polymerase III to drive 
transcription, those developed at CSHL make use of the RNA polymerase II promoter.   
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Furthermore, we express hairpin RNAs in the context of a natural miRNA, miR-30 (125 
bases 5’ and 3’ of the pri-miR-30 sequence), to mimic the pri-miRNA for RNAi.  This 
strategy has proven to be up to 12 fold more efficient than other designs in causing gene 
silencing.   
Specifically, I have utilized the Version-2 library (V2), which contains approximately 
10,000 shRNAs with 2-3 dedicated shRNAs per gene.  This second-generation Hannon-
Elledge shRNA library is a collection of ten thousand shRNAs covering roughly three 
thousand genes that have been shown to be involved in tumorigenesis. The shRNAs in the 
library are directed against genes involved in kinase or phosphatase signaling, the cell cycle, 
apoptosis, transporter activity and the cytoskeleton (Silva et al. 2005). The 22-nt sequences 
that comprise the shRNAs were designed by Rosetta Inpharmatics (Kirkland, USA) using 
proprietary algorithms based on empirical testing of thousands of siRNAs.  These 
algorithms introduce positional biases and thermodynamic rules suggested by analysis of 
siRNA and endogenous miRNA incorporation into the RISC complex.  The V2 library exists 
in multiple forms differing in the vector used as a vehicle for shRNA delivery.  The one used 
is based on the pSMP retroviral vector, which was developed to maximize expression of the 
shRNA to allow gene silencing at single copy viral integration. 
A particular feature of note for the library is its traceable shRNA expression.  
Because it utilizes RNA Pol II to drive the shRNA expression, a reporter fluorescence 
marker (i.e., GFP) can be directly placed in front of the Mir30-shRNA cassette. The reporter 
can thus faithfully track shRNA expression quantitatively. This feature enables one to select 
for cells with the desired level of knockdown. Additionally, the presence of a unique 60 
nucleotide sequence for each plasmid allows for the identification of a specific shRNA 
vector within a pooled population. Hence, unlike RNAi libraries that can only be screened 
in a well-by-well format, the presence of the unique bar-coding system allows screening to 
be conducted in a pooled manner.   
As mentioned earlier, pooled shRNA screens are in principle lower in cost and more 
flexible to perform.  To identify shRNAs that confer the desired phenotype in the library, the 
composition of shRNAs in the pool at the end of the assay is compared with the 
composition of the pool at the beginning of the assay. To this end all shRNAs that have been 
integrated in the genome are PCR-recovered as a single mixture using universal primers 
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directed against the vector back-bone. The abundance of each shRNA in the mixture is then 
measured either by hybridization on custom made microarray containing the complement 
barcode sequences of the entire shRNA library or by next-generation sequencing of the 
genomic DNA extracted from the pool of cells.  
By using this methodology, I set out to perform a functional genomic screen in lung 
adenocarcinoma cell lines that express mutant EGFR and/or PDGFR and that are sensitive 
to the molecular inhibition of either of these RTKs. The screens in this study where designed 
to be either straight lethal or synthetic lethal screens. Straight lethal screens identify shRNAs 
that kill cells over time. These lethal shRNAs often identify genes that effect growth and 
survival and are thus selected out over time (Silva et al. 2008). Treatment of certain cells 
with kinase inhibitors in combination with shRNAs have been shown to produce a synthetic 
lethal effect (O’Connell et al. 2010; Bivona et al. 2011).  
The first screen I performed was in the NSCLC cell line H1703. This NSCLC cell line 
displays overexpression and activation of PDGFR, as well as increased sensitivity to 
treatment with a specific PDGFR inhibitor. As a first step, I amplified the 10K second-
generation shRNA library and prepared it for transfection. The library was then transfected 
into an amphotropic phoenix packaging cell line. Virus produced by this packaging cell line 
was then used to infect H1703 cells. To achieve a good representation, I infected more than 
500 cells per individual shRNA, with a target of 1000 cells per shRNA. Each experiment was 
conducted in triplicate in 15-cm dishes. Some of the cells were harvested (T0) after 48h, 
when the virus was anticipated to have integrated into the genome and is expressed at very 
low level. Cells were then selected in puromycin to generate a uniform cell population 
expressing the shRNA library. After 72h on puromycin selection were completed, H1703 
cells were allowed to recover for one week and then trypsinized; half of the cells were 
collected (T1), and the rest were utilized for further treatment with selective RTK inhibitors 
at two different concentrations (IC20 and IC80). For H1703 cells, we used a specific PDGFR 
inhibitor and DMSO as a control for the drug treatment (IC0). Only after the DMSO control 
plate reached confluency, a subset of cells was collected again (T2). The remaining cell 
population was maintained under inhibitor treatment for approximately 2 more weeks and 
again collected (T5).  
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After all the collections were performed, genomic DNA was extracted for each time 
point. The shRNAs were then amplified using barcode-specific PCR primers followed by gel 
extractions to provide high-quality DNA for microarray. The PCR products were then 
differentially labeled with two dyes: Cy-3 was used to label the sample library and Cy-5 was 
used to label the control library. Control and sample libraries were mixed in equal amounts 
and applied to the chambers of the microarray slides. Ideally, large amounts of DNA should 
be labeled and purified. To reduce variation, in our screen we always hybridized 1micro-
gram or more to an Agilent array containing the complement barcode sequences of the 
entire shRNA library (Figure A.2.1.A).  
The microarray was then scanned, and the results were analyzed by Joel Parker, a 
bioinformatician consulting for the Hannon lab, using a variety of statistical techniques, 
such as principal component analysis (PCA) and false discovery rate (FDR) (Figure A.2.1). 
Comparison of shRNA expressed at T0 vs. subsequent time points provided a list of lethal 
genes whose expression was required for the survival of the cells. In addition, the synthetic 
lethal genes were identified by measuring the abundance of barcodes within the mixed 
population of the enriched or depleted shRNAs resulting from treatment with the TK 
inhibitors (Figure A.2.1.D).  
The normalization plots showed that 9256 probes were found in all 9 T0 samples, 
suggesting that a high-quality percentage had been obtained from the 10K library (Figure 
A.2.1.B). The principal component graph also suggested a technical variation between chips 
and between different hybridizations for each screen, indicating selection of particular 
shRNAs over time (Figure A.2.1.C).  
Next, I performed a screen in two more NSCLC cell lines, a cell line resistant to 
erlotinib that contains two EGFR mutations (H1975) and a cell line sensitive to erlotinib 
(H4006). H4006 cells contain an 18 bp in-frame deletion found in exon 19. Also in this case 
the normalization plots reflecting the negative controls to select hairpins measured for both 
screens resulted in 9,555 hairpins for further analysis (Figure A.2.2.B).  PCA indicated that 
the primary variation between screens was due to differences in cell lines. In addition, the 
repeatability within each of the experimental conditions was high, with median probe 
coefficients of variations less than or equal to 6%. 
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Additionally, we determined genes that when silenced produce a straight lethal 
effect (T0 unselected vs. T5 selected) in all the cell lines we analyzed (H1703, PC9, H4006, 
H1650, H1975 and M3 -a derivative of H1650 that is resistant to erlotinib) (Figure A.2.2).  
The data are still very preliminary, further statistical and bio-informatics analysis is 
needed to identify common and unique synthetic lethal genes in erlotinib sensitive cell lines 
(PC9, H4006, and H1650) and resistant cell lines (H1703, H1975 and M3). These candidate 
genes will then have to be thoroughly validated in subsequent endeavors. 
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Figure A.2.1. Functional genomic shRNA library screen performed in H1703 NSCLC cells. A) Probes are identified based on 
their intensity. Density correlates to the number of probes on the array that have signal for the reference library (Cy3). B) The 
histogram based on the H1703 screen reports the number of probes that were included in downstream analysis. There were 
9256 probes found in all T0 samples. C) The 1703 screen had high reproducibility shown by a low standard deviation. The 
mean correlation is shown for the replicates over time. T5 are divided between IC20 and DMSO treatments for two parallel 
screens (SK1 and SK2). T0 has the highest correlation, while T5-SK1 has the lowest. Error bars report standard error. D) Heat 
map produced for H1703 screen treated with PDGFR inhibitor for 2 weeks. Hairpins underrepresented are shown in green, 
red are over abundant. Samples treated with IC20 of PDGFR inhibitor (Left Red Box) and DMSO control (Right Black Box). 
A 
B 
C 
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Figure A.2.2. Completion and analysis of additional functional genomic screens for other NSCLC cell lines. A) Diagram of all 
NSCLC cell lines according to their respective sensitivity status to the RTK inhibitors. B) Normalization plots found 10,066 
shRNAs in all T0 samples used for further analysis. C) Principal component analysis of H1650, M3, PC9, H4006, H1975 and 
H1703 straight lethal genomic screen. 
A B 
C 
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MATERIALS AND METHODS  
 
Cell culture 
H1650 (H1650), H1703 (NCI-H1703), H1975 (NCI-H1975), HCC4006 were obtained 
from the American Type Culture Collection (ATCC) repository. All the cell lines were 
cultured in RPMI supplemented with 5% FBS, glutamine, penicillin, and streptomycin. The 
lentiviral packaging cell line HEK293T was cultured in DMEM containing 10% FBS, 
penicillin, streptomycin, and sodium pyruvate. 
 
Antibodies and reagents 
The following antibodies were used in this study: mouse anti-Flag M2 (F1804, 
Sigma), rabbit anti-PDGFRα (3164, Cell Signaling Technology), mouse anti-phosphotyrosine 
clone 4G10(05-321, Millipore), mouse anti-RASGAP antibody (BD Transduction 
Laboratories), mouse anti-STAT3 antibody (124H6, Cell Signaling Technology), and rabbit 
anti- phospho-STAT3 antibody (D3A7, Cell Signaling Technology), goat polyclonal anti-
SOCS3-M20 antibody (sc-7009, Santa Cruz Biotechnology), mouse anti-beta-Tubulin 
antibody (2-28-33, Santa Cruz Biotechnology).  
erlotinib hydrochloride was purchased from LGM Pharmaceuticals, Inc. Recombinant 
interlukin-6 (rhIL-6), were obtained from R&D Systems. Human recombinant PDGF-BB was 
purchased from Millipore. For stimulation, the cells were starved in medium without fetal 
bovine serum and treated with 10 ng/ml IL-6 and 1 ng/ml PDGF-BB. The inhibitor MG132 
(Calbiochem) was dissolved in DMSO and used at a concentration of 10 um. 
 
Preparation of lysate from cell culture 
The cell culture dish was placed on ice and washed with ice-cold PBS. The PBS was 
drained, and then ice-cold lysis buffer was added (1 ml per 107 cells/100mm dish/150cm2 
flask; 0.5ml per 5x106 cells/60mm dish/75cm2 flask). Adherent cells were scraped off the 
dish using a cold plastic cell scraper; the cell suspension was transferred into a pre-cooled 
eppendorf tube. In a microcentrifuge at 4°C all samples were centrifuged for 30minutes at 
13,000 rpm. The tubes were removed from the centrifuge and placed on ice, the supernatant 
was transferred into a fresh 1.5ml eppendorf tube always maintained on ice, and the pellet 
was discarded. 
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Lysis buffers 
RIPA buffer (Radio Immuno Precipitation Assay buffer) 50mM Tris  pH. 8.0, 150mM 
NaCl, 0.1% SDS (sodium dodecyl sulphate), 0.5% Sodium deoxydolate, 1.0% Triton X-100 in 
H20 and filtered with Corning 0.22µm stored at 4˚C for up to 3 Years. To prevent 
proteolysis, dephosphorylation and denaturation from occurring the inhibitors below were 
always added fresh to the lysis buffer before the cell collections. For all western blots we 
used ready to use Cocktail 25X (Invitrogen), NaF (10mM), NaVn (0.1M) and DTT (0.5mM). 
  
Determination of protein concentration 
Perform a BCA (bicinchoninic acid) assay (Thermo Scientific Pierce). Using Bovine 
serum albumin (BSA) as the protein standard. RIPA buffer with protease and phosphatase 
inhibitors was used to dilute the standards into six decreasing concentrations of BSA 
(20µg/µl). The amount for each reagent A and B was calculated and mixed in a falcon tube 
for a minute. All samples were measured in triplicates using 2µl in each well plus 50µl of the 
BCA mixture and incubated for 30 minutes at 37˚C. The BCA/copper complex is water-
soluble and exhibits a strong linear absorbance at 562 nm with increasing protein 
concentrations. Plates were read using SpectraMax 190 from Molecular Devices provided by 
the Tonks Laboratory and analyzed using SOFTmax PRO software. The concentration of 
each sample was determined and 20ng for all protein samples was calculated for loading. 
Samples were either frozen at -20°C or -80°C for later use or prepared for 
immunoprecipitation or for loading onto a SDS-PAGE gel using 6X Laemmli buffer. 
 
Western Blotting 
Western blots were used to confirm the overexpression or knockdown of shRNAs on 
specific proteins as well as to assess the effects on cellular signaling mechanisms. Western 
blots were performed using either Laemmli 6X or RIPA buffer. SDS-PAGE (for Sodium 
Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis) was performed and wet transferred at 
4˚C into nitrocellulose membranes. To check for success of transfer the membrane was 
stained with Ponceau Red and blocked with 5% milk or BSA solution. Blots were scanned 
on the Odyssey Fluorescent Scanner using secondary antibodies from Licor Biosciences. 
(926-32212 IRDye 800CW Donkey anti-Mouse IgG, and 926-32211 IRDye 800CW Goat anti-
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Rabbit IgG). Pierce ECL Western Blotting Substrate was also used with HRP-conjugated 
secondary antibodies from GE Healthcare (Rabbit IgG, HRP-Linked F(ab)2 Fragment from 
donkey and ECL Mouse IgG, HRP-Linked F(ab')2 Fragment (from sheep). Blots were 
exposed to autoradiographic films for one to three minutes and then developed using 
Kodak XoMat 2000A. 
 
Protein Expression 
The pGEX-6P-1 GST expression vector containing SOCS3 WT, FFIF, DDID cDNA 
were transformed into E. coli strain, BL21(DE3) and plated in LB-amp Agar plates. 
Individual colonies were inoculated in 5ml of LB-amp overnight and grown at 37˚C (until 
A600 = 1-2). Pre-culture was diluted into 150 mL LB-amp broth and cultures were grown 
with shaking (250 rpm) for 1-2 hours at 37˚ C (until A600 = 0.5). Then, expression of fusion 
proteins was induced by adding isopropyl-ß D-thiogalactoside (IPTG) to 0.1 mM final 
concentration and the cells were allowed to grow for an additional 3-5 hours at 37°C. Cells 
were harvested by centrifugation at 4000 rpm for 10 min, supernatant was discarded, pellet 
was suspended in 1mL of lysis buffer, and sonicated to lyse cells at 50% duty cycle for 5min 
each. Cell debris was spinned down and stored at -80C  or incubated with washed 
glutathione beads at 4C from 4-16h rotating. Samples were treated with 1X SDS-PAGE 
buffer, run on SDS- PAGE and stained with Coomassie Blue. 
 
In vitro GST-SOCS3 Kinase Assay  
500 ng to 1µg/ml of glutathione S-transferase-tagged proteins (wt and mutants 
SOCS3) were first incubated with Glutathione beads previously washed and resuspended in 
binding buffer (50 mM Tris pH 7.4, 150 mM NaCl, 2 mM EDTA) for 4 hours to overnight at 
4˚C with constant agitation. The beads-protein complexes were washed 3 times with 
washing buffer (50 mM Tris pH 7.4, 150 mM NaCl, EDTA 2 mM, NP40 1%) and then 
incubated with 100ng of kinase for 2 hours at 30˚ C or 1 hour at 37˚ C with agitation in 10 
mM MOPS, 1 mM EGTA and 0.1% Triton X-100 0.1 mM Na3VO4 (reaction buffer), and 10 
mM MnCl2, 1 mM DTT, 0.5 mM Na3VO4, 0.5 mM NaF3, Mg2+ and ATP mix (Millipore 1:1 
dilution) diluted in 2.5 mM Hepe pH 7.4, 50 mM, 0.5mM ATP with 1 mCi/100µl y-[32P] 
ATP (3000Ci/mMol) to allow visualization of phosphorylation via autoradiography and 
phosphor imaging reaction were terminated by adding Laemmli buffer. After incubation, 
 121
the reactions were boiled and subjected to analysis by SDS-PAGE. Radioactive signals were 
detected using a Fujifilm FLA-5100 instrument (Fuji Medical Systems USA, Inc.), and band 
intensities were quantified using Multi- Gauge v2.3 software (FujiFilm). 
 
Steady-State Kinetics 
Michaelis/Menten analysis requires the use of a high enzyme-to-substrate ratio so 
that product formation is linearly proportional to time. Substrate concentration must be 
RKM to approach saturation and allow accurate determination of Vmax. Therefore, 100 nM 
either EGFR or PDGFR were used to phosphorylate 0–5 mM GST-SOCS3 WT in these 
assays. The reactions were performed as for the kinase assay described above, but in the 
presence of decreasing concentration of substrate. After incubation, the reactions were 
imaged as above and analyzed using Prism 5 (GraphPad Software). 
 
Peptide library screen 
The peptide library that employed was synthesized by Primm, Biotech Inc. on a scale 
of 5 mg per peptide mixture. Degenerate positions were prepared by coupling mixtures of 
the 20 naturally occurring amino acids. Crude peptide mixtures were dissolved in DMSO 
and quantified by absorbance at 280 nm. Stock solutions were adjusted to 25 mM by adding 
the appropriate volume of DMSO and stored at –20ºC. Working 0.5 mM aqueous stocks 
were prepared by diluting the DMSO stock rapidly into 50 mM HEPES, pH 7.4. Aqueous 
solutions were aliquotted into 96-well polypropylene stock plates in 40 µl aliquots, sealed 
with aluminum adhesive foil, and stored at –20ºC.  
Assays were performed by dispensing reaction buffer (40 mM MOPS, pH 7, 1mM EDTA) 
into 96-well plates. Peptides were transferred to assay plates from stock plates manually 
using a multi-channel pipette. Reactions were initiated by adding reaction buffer containing 
400 µM cold ATP with 0.1-0.2 µCi/µl ã-[32P]-ATP and protein kinase diluted in (20mM 
MOPS, pH 7.0, 1 mM EDTA, 5% glycerol, 0,1 mercaptoethanol 1mg/ml BSA). The final 
concentrations of the reaction components will be 50 µM peptide and 100 µM ATP at a 
specific activity of 0.25-0.5 mCi/pmol. The concentration of ATP corresponded to 
approximately 5 times the predicted km using an optimal peptide as substrate (e.g. 
DNDYINA).  
 122
Approximately 10 ng of kinases were used per well, and kinase reactions were incubated at 
30ºC for 30 minutes (linear range). After completion 5ul from each reaction were spotted 
onto avidin-coated filter sheets (Promega SAM2 biotin capture membrane). Spots occupy 
approximately 16 mm2 area and contain 100 pmol peptide; according to the manufacturer 
the membrane capacity for this area is 200 pmol. Membranes were washed three times with 
10 mM Tris-HCl, pH 7.4, 140 mM NaCl, 0.1% SDS, three times with 2 M NaCl, twice with 2 
M NaCl, 1% H3PO4, and twice with water, dried, and exposed to a phosphorimager screen 
overnight. Radioactive signals were detected using a Fujifilm FLA-5100 instrument (Fuji 
Medical Systems USA, Inc.), and spot intensities were quantified using Multi- Gauge v2.3 
software (FujiFilm). 
 
Immunoprecipitation (IP) 
Approximately, 3×107 cells were lysed in 500–1000 µl of lysis buffer (1% Triton X-
100, 20 mm Tris/HCl (pH 7.6), 150 mm NaCl, 10 mm NaF supplemented with 1 mm 
Na3VO4, 1 mm phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 5 
µg/ml pepstatin, and 10 um MG132) for 30 min at 4 °C. Insoluble material was removed by 
centrifugation, and cell lysates were precleared with washed protein A-Sepharose beads 
(Amersham Biosciences) for 1 h at 4 °C collect input. After removal of the Sepharose, the 
lysates (1–3 mg of protein) were incubated overnight rotating with EZview Red ANTI-
FLAG M2 Affinity Gel (F2426, Sigma-Aldrich) at 4 °C. After centrifugation the beads were 
washed 3 times with washing buffer (0.1% Triton X-100, 20 mm Tris/HCl (pH 7.6), 150 mm 
NaCl, 10 mm NaF, 1 mm Na3VO4).  
 
Immunoblots 
Immunoprecipitates were eluted by boiling in 1X Laemmli buffer at 95°C for 5 min 
and resolved by SDS-PAGE, transferred to nitrocellulose membranes (Bio-Rad), and blotted 
with antibodies as indicated. 
 
Mammalian expression vectors 
A Flag tag encoding sequence was added to the N terminus of SOCS3 wild-type and 
mutant by PCR, and the resulting fragments were cloned into EcoRI/BamHI sites of into 
pMSCV- pTREtight-GFP with rtTA-IRES-Hygro (a gift from S. Lowe, CSHL). All constructs 
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used in this study were sequence verified. SOCS3 wt and mutant were PCR amplified from 
the vector above and ligated into pEntry4 and recombined into pLenti6/UbC/V5-DEST™ 
Gateway® Vector (Invitrogen™). 
 
PCR and mutagenesis  
PCR was performed using 5µl of cDNA in a total of 100µl reaction mixtures 
containing 10 µM deoxynucleoside triphosphate (dNTP) mix (Roche), 10µl of ThermoPol 
buffer (NEB), 1µl of Taq DNA polymerase (NEB), and 1mM each primer. Amplification of 
SOCS3 was performed using the following primers: 
 EcoRI-flag-socs3-F: 
5’GGAATTCATGGACTACAAGGACGACGATGACAAGCTCGATGGAGGAatggtcacccaca
gcaag-3’  
BamHI-flag-socs3-R: 
5’gcggatccTCAGGCGTAGTCGGGCACGTCGTAGGGGTAaagcggggcatcgtactg-3’ 
BamHI-Flag-SOCS3-F: 
5’ggatccATGGACTACAAGGACGACGATGACAAGatggtcacccacagcaa-3’ 
ECORI-SOCS3-R: 5’-GGAATTCAAGCGGGGCATCGTTACTG-3’  
Mutagenesis primers 
SOCS3_DDID_F 5’-AGCCGATGACATCGACTCCGG-3’ 
SOCS3_DDID_R 5’-GTCGATGTCATCGGCTCTTCT-3’ 
SOCS3 FFIF_F 5’-AGCCTTTTTCATCTTCTCCGG-3’ 
SOCS3 FFIF_R 5’-GAAGATGAAAAAGGCTCTTCT-3’ 
SOCS3 FFID _F 5’-AGCCTTTTTCATCGACTCCGG-3’ 
SOCS3 FFID_R 5’-GTCGATGAAAAAGGCTCTTCT-3’ 
SOCS3 FDIF_F 5’-AGCCTTTGACATCTTCTCCGG-3’ 
SOCS3 FDIF_R 5’-GAAGATGTCAAAGGCTCTTCT-3’ 
SOCS3 DFIF_F 5’-AGCCGATTTCATCTACTCCGG-3’ 
SOCS3 DFIF_R 5’-GAAGATGAAATCGGCTCTTCT-3’ 
PDGFR cloning 
PDGFRA_F1 5’-TGAAGGCACGCCGCTTCCTG-3’ 
PDGFRA_R1 5’-ACGGCCCTCCACGGTACTCC-3’ 
PDGFRA F2 5’-CGCCAGGCTACCAGGGAGGT-3’ 
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PDGFRA R2 5’-CAGGAAGCGGCGTGCCTTCA-3’ 
PDGFRA F3 5’-CGCCAGGCTACCAGGGAGGT-3’ 
PDGFRA R3 5’-CCAGGACTGCAGCAGCCACC-3’ 
PCR parameters used for cDNAs prepared from H1650 cells were 95°C for 5 min, 
followed by 35 cycles at 95°C for 45 s, 56°C for 30 s, and 72°C for 1min, and a final step at 
72°C for 10 min. PCR products were separated on 2% agarose gels and visualized by 
ethidium bromide staining using the U:Genius imaging system (Syngene). PCR products 
were purified using PrepEase® Gel Extraction Kit (USB) and digested, ligated into 
destination vector described above. Positive clones were sequenced verified. Mutagenesis of 
SOCS3 was performed using RACE (rapid amplification of cDNA ends). Modified sequence 
primers used for each construct are shown above. 
PDGFR cloning was also performed in sections since it is a long transcript of more 
than 3.2Kbases. Sections were amplified with the primers above from the inside and then 
utilized outside primer with EcoRI/BamHI sites for blunting ends and ligating to tTiGFP 
vector.  
 
FACS analysis 
H1650 over-expressing cells and all other NSCLC cell lines were grown in RPMI 
media supplemented with 5% FBS, sodium pyruvate, penicillin, and streptomycin. Cells 
were harvested at 70% confluency, dissociated and washed in PBS with 5% FBS. Following 
this wash, cells were pelleted and resuspended in solution containing PBS (pH 7.2), 0.5% 
bovine serum albumin, and 2 mM EDTA. Counting experiments were performed using an 
LSR II flow cytometer (Becton Dickenson); 100,000 events were collected for each sample. 
Sorting experiments were done with a BD FACS Aria II cell sorter for GFP cells. Gates were 
set using H1650 as a reference population. 
 
Mouse model system 
The in vivo mouse experiments were performed by inoculating 3 × 106 H1650 
subcutaneously into each flank of immunodeficient Nu/Nu mice on Swiss CD1 background 
(Charles River Breeding Laboratories). Mice were given Doxycicline in water after a month. 
After the tumors reached a volume of approximately 100 mm3, tumors were weighted and 
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mice dissected for metastasis. Organs with metastatic sites were imaged and stored in fixed 
solution.  
 
Drug curves 
Drug curves are performed in 96 well plates. Cells are grown in 10cm plates until 
they are ~80 percent confluent and growing well. They are then trypsinized and counted. 
Cells are plated at a density of 2,000 cells per well in a 96 well plate. Cells are allowed to 
attach overnight and then treated with serial dilutions of erlotinib (or other drug). Serial 
dilution is performed in a 12 well reservoir and then delivered to the plate using 
multichannel pipettes. After 72 hours of drug treatment, cells are washed twice with PBS 
and then fixed with 4% formaldehyde. Then, cells are washed with water to remove excess 
formaldehyde and stained with Syto-60 (Invitrogen) to stain DNA. Plates are washed with 
water again to remove excess stain. Plates are read in the Licor Odyssey scanner. 
Fluorescent intensities of each 96well are recorded and the images are then analyzed using 
the Licor software. Averages over each set of wells is generated and compared to the 
untreated control and reported as percent survival of control, untreated populations.  
 
siRNA-based gene knockdown 
To target the SOCS3 gene, commercially prepared Stealth RNAi siRNAs I) 
HSS113312 and II) HSS113313 III) HSS113313 were obtained from Invitrogen. siRNAs were 
transfected into cells using Lipofectamine 2000 (Invitrogen) as per the manufacturer's 
instructions. Two days after transfection, mRNA levels were determined by RT-PCR and 
protein levels were determined by lyzing the cells in RIPA buffer as previously described. 
Stable knockdown was obtained even at 10 days following transfection. mRNA levels were 
assessed by RT-PCR. 
 
RNA extraction and quantitative RT-PCR 
Total RNA was collected from cultured cells and purified using Trizol reagent 
following the manufacturer’s instructions (Invitrogen). Total RNA (500 ng) was subjected to 
a reverse transcriptase reaction using the Improm-II Reverse Transcriptase kit (Promega). 
cDNA corresponding to approximately 1% of the RNA was used in three replicates for 
quantitative PCR with the SYBR GREEN (Applied Biosystems) labeling or for standard 
PCR. Indicated Taqman gene expression assays (Applied Biosystems) and the Taqman 
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universal PCR master mix (Applied Biosystems) were used to quantify gene expression. 
Quantitative expression data were acquired and analyzed using an ABI (Applied 
Biosystems) Sequence Detection System. Primers are listed as follows: SOCS3: Forward 
Primer GCCAAGAGGGCGACAAGTT, SOCS3 Reverse Primer 
AGGAAAACAGCATACTCCTGGA.  
 
In-gel Digestion and Protein Identification Using Mass Spectrometry 
Silver-stained protein bands were excised from one-dimensional SDS gels and cut 
further into small cubes (∼1 × 1 mm). After in-gel reduction, alkylation, and distaining, the 
proteins were digested overnight with trypsin (12 ng/µl). The tryptic peptides were 
extracted from gels dried in a vacuum centrifuge and analyzed by electrospray liquid 
chromatography-tandem mass spectrometry using a nanoscale C18 column coupled in-line 
with an ion trap mass spectrometer (LCQ Deca, Thermo Finnigan). The instrument was set 
in a data-dependent acquisition mode, cycling between one full MS scan and MS/MS scans 
of the three most abundant ions. The MS and MS/MS data were used to search the 
nonredundant NCBI protein database using the MASCOT search engine. 
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